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Abstract 
After the discovery of acridine in the late 1800's, the acridine class of molecules 
attracted much synthetic interest due to their usefulness as dyestuffs and the 
discovery that certain acridine derivatives possessed anti-bacterial properties.  It 
was this discovery that lead aminoacridines to be used heavily as anti-bacterial 
agents until they were supplanted by the use of sulfonamides and the discovery 
of the penicillin's.  Despite falling out of favor as anti-bacterial agents, acridine 
derivatives were still used in the treatment of other diseases such as malaria and 
cancer. 
Despite falling out of use as anti-bacterial agents, one area where the acridine 
class of compounds may find a new use is in the treatment of drug-resistant 
bacterial infections, namely MRSA.  Infections caused by numerous drug-
resistant bacteria have become a major health issue in the world today which has 
led to a pressing need for the development of novel agents to treat these 
infections. 
We report within this thesis the synthesis and evaluation of numerous acridine 
and acridone based compounds that possess activity against a number of strains 
of MRSA.  In an attempt to elucidate a potential mechanism of action, the active 
compounds were also tested in DNA intercalation assays and screens against 
other known bacterial targets.  Despite our best efforts, the mechanism of these 
novel acridine compounds was not elucidated and is hypothesized to be an 
interaction with the bacterial cell membrane. 
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Chapter 1:  Synthetic Methods to Access Acridines  
Bernthsen Acridine Synthesis: 
Acridine, first isolated in 1870 from coal tar,1 has attracted significant synthetic 
attention over the years.  In 1884, Bernthsen reported the first synthesis of 
acridine in which diphenylamine was condensed with benzoic acid using zinc 
chloride and high temperatures (Figure 1).2 
 
Since this first synthesis of acridine by Bernthsen, what has come to be known 
as the Bernthsen Acridine Synthesis has been used to synthesize numerous 9-
substituted acridine analogs by varying the carboxylic acid coupling partner.   
Due to the fact that the original Bernthsen synthesis often suffered from low 
yields and the need for each set of reaction conditions to be dependent on the 
substrate,3 there is much room for improvement on the reaction to provide better 
yields with less variation of conditions between substrates.  One major 
improvement of the Bernthsen synthesis came in 1961 when Popp reported the 
use of polyphosphoric acid (PPA) as both the solvent and acid in the Bernthsen 
acridine synthesis.  In using PPA instead of zinc chloride, Popp found that 
reaction times could be shortened greatly from 24 hours to 15 minutes (Figure 
2).  It was also found that reaction between electron rich substrates such as p-
aminobenzoic acid and diphenylamine were successful using Popp's method 
H
N
R OH
O
N
R
ZnCl2
200-270 oC
24h
+
Figure 1:  General scheme of the Bernthsen Acridine Synthesis 
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while the original synthesis failed to afford any desired acridine.  However as with 
the original synthesis, acridines made from electron deficient substrates such as 
p-nitrobenzoic acid were still not accessible.4 
 
The most recent improvement to the Bernthsen synthesis has been using a 
microwave reactor instead of the traditional thermal methods used in both the 
original synthesis and Popp's modification.  In 2002 it was reported that using the 
original zinc chloride conditions (Scheme 3), 9-substituted acridines made from 
both aromatic and aliphatic carboxylic acids could be made in good yields with 
short reaction times using microwave assisted synthesis.5  The newest report in 
2011 allowed for the replacement of zinc chloride with p-toulenesulfonic acid as 
the catalyst (Figure 3) to afford a wider range of 9-substituted acridines, 
including ones derived from electron poor carboxylic acids which were previously 
inaccessible using the Bernthsen reaction.6 
 
 
 
Figure 3:  Microwave assisted Bernthsen reactions 
 
Figure 2:  Popp's use of PPA in the Bernthsen Acridine Synthesis 
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Ullmann Synthesis: 
While the Bernthsen synthesis has been used to make a large number of 
acridines, the most common route to synthesizing acridines is via cyclization of 
N-phenylanthranilic acid derivatives.7  The synthesis of these derivatives was first 
described in 1885 by Jourdan via a coupling of an aryl halide and an aryl amine.  
The reaction only proceeded with strongly electron withdrawing groups that 
activated the aryl amine.8,9  In 1903, Fritz Ullmann demonstrated that the addition 
of copper to the coupling reaction allowed for facile coupling of non-activated aryl 
amines with aryl halides.10  This discovery lead to the copper catalyzed coupling 
between aryl halides and aryl amines to be known as the Ullmann reaction 
(sometimes also called the Ullmann-Jourdan reaction).7  Shown below in Figure 
4 is the general reaction scheme of the Ullmann reaction. 
 
As mentioned, copper is required as a catalyst for non-activated anilines.  At 
least one equivalent of base is also required as one equivalent of HX (where X 
can be F, Cl, Br, or I) is liberated in the course of the reaction.  There is a great 
variation on possible solvents with most reactions being run in water,11 higher 
boiling alcohols (amyl alcohol being common),9,7 or DMF.12  The use of high 
temperatures, generally greater than 100 °C is required for the reaction to 
 
Figure 4:  General scheme of the Ullmann reaction. 
4 
 
proceed, though lower temperature variants have been discovered in more 
recent years.13   
Though the exact mechanism of the reaction is still not fully known and likely 
varies between coupling partners and the exact reaction conditions, there has 
been a large volume of work trying to elucidate the probable mechanisms of the 
Ullmann reaction.  Shown in Figure 5 one of the first mechanisms proposed is 
the formation of an aryl copper(III) species that undergoes nucleophilic attack by 
the aniline.7,14  This mechanism can also be used to explain some of the 
difficulties such as the production of side products common with the Ullmann 
reaction as generally alcohols or water are used which can also undergo 
nucleophilic attack on the aryl copper(III) intermediate.7 
a
 
Rather than the oxidative addition of the copper into the aryl-halogen bond 
happening first to afford the copper(III) intermediate, recent research suggests 
that a copper-aniline complex actually forms first and this complex is what 
undergoes oxidative addition to the aryl-halogen bond followed by subsequent 
reductive elimination to afford the desired N-phenylanthranilic acid.15   
The other major suggested pathway that has garnered a lot of attention has been 
the possibility of the reaction proceeding through a single electron transfer (SET) 
 
Figure 5:  Proposed mechanism of the Ullmann reaction proceeding through a 
Cu(III) intermediate.  Figure adapted from reference 7. 
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mechanism.  The radical mechanism of nucleophilic aromatic substitution 
reactions first was proposed in 1937 by Waters.16  Originally the radical 
mechanism was merely speculation, however in the 1960's, extensive work was 
done to show that a single electron transfer (SET) mechanism was a plausible 
pathway.15   
Work done by Bunnett looking at the amination of 5- or 6- substituted 
halopesudocumines proposed that if the reaction proceeded through an aryne 
mechanism, that there should be an equal ratio of the possible products.  In the 
case of the iodopseudocumine, the expected product ratio was vastly shifted 
which suggested an alternate to the proposed aryne mechanism.  To elucidate 
this possible mechanism, Bunnett used triphenylhydrazine as a radical 
scavenger and noted the ratio of products was back in line with what is expected 
from the aryne mechanism.  This finding lead to some of the first evidence of a 
SET mechanism and the designation SRN1 (substitution, radical-nucleophilic, 
unimolecular) for this type of reaction.17   
Although there was much more research into the SET mechanism, it was not 
until recently that a computational study by Houk and co-workers provided 
excellent evidence for the viability of the SET pathway.18  Further experimental 
evidence that has helped solidify the SET mechanism as a viable pathway, came 
in a 2012 study by Peters in which they showed an Ullmann coupling catalyzed 
by copper and light did in fact proceed through a radical mechanism.19  With the 
probable mechanisms of the Ullmann reaction elucidated coupled with vast 
improvements allowing for milder reaction conditions, the Ullmann reaction for 
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the formation of C-N bonds to form various substituted N-phenylanthranilic acids 
which can be cyclized to acridines, is still a useful transformation 110 years after 
its discovery. 
Buchwald-Hartwig Amination 
Despite recent improvements to the Ullmann reaction to couple aryl halides to 
aryl amines that can be cyclized to acridines, the reaction still has its drawbacks, 
especially with coupling partners bearing electron donating substituent's.20  An 
efficient coupling reaction for any aryl amine and aryl halide combination, 
including coupling partners with electron donating groups, was first reported in 
1983 by Migita and was catalyzed by palladium in the presence of tin.21  This 
reaction was further improved by removing the need for tin and reported on by 
both Buchwald and Hartwig in 1995 in a reaction that has subsequently become 
known as the Buchwald-Hartwig amination reaction.22,23   
The Buchwald-Hartwig amination reaction has become one of the main reactions 
used in both academia and industry to afford the C-N bond in anilines and 
anthranilic acids due to its extremely broad substrate scope.24  This has come 
through a very large volume of work done optimizing the reaction that has lead to 
its generality.  When it was first reported, the amination reaction had a limited 
scope and as to which combinations of aryl halide, amine, base, and solvent that 
would work well.  One example is in the first report by Hartwig, aryl iodides 
performed very poorly in this reaction.23  This however changed upon the 
discovery of the second generation of catalysts that used palladium with DPPF 
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as the ligand.  This allowed for near quantitatitive coupling of primary amines to 
aryl iodides.25,26 
The mechanism of the reaction occurs via the catalytic cycle shown below in 
Figure 6.  The first step of the reaction is the oxidative addition of the aryl halide 
to the palladium-ligand complex.  In the case of the amination reaction, the base 
deprotinates the nucleophile, which in this case is the amine.  The nucleophile 
adds to the palladium-ligand-aryl complex and a reductive elimination step 
regenerates the palladium-ligand complex and frees the newly formed C-N 
coupling product.27 
 
With the Buchwald-Hartwig amination reaction optimized to have a very broad 
scope of reactivity, there is very little work reported on using the reaction to form 
N-phenylanthranilic acids that are cyclized to acridines.  The one report citing the 
reaction directly as a vast improvement over the Ullmann reaction was a paper 
 
LnPd(0)
Ar-X
LnPdArX
Nu-H, BaseBase, HX
LnPdArNu
Ar-Nu
 
Figure 6:  Catalytic cycle of the palladium catalyzed coupling of aryl iodides to 
amines.  Figure adapted from reference 27. 
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by Czuk and Raschke that examined a range of electron withdrawing, neutral, 
and donating coupling partners that were cyclized to acridines using standard 
methodology.7  Despite its limited use reported in the literature, the reaction was 
used successfully by our laboratory to access acridine derivatives that were 
otherwise problematic to access using the Ullmann reaction. 
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Chapter 2:  Anti-Bacterial Drug Resistance 
Methicillin resistant Staphylococcus aureus (MRSA): 
Supplanting the use of the earliest antibiotics and ushering in what some call the 
"antibiotic era", the use of penicillin in the early 1940's drastically changed the 
way we deal with bacterial infections.28  Along with the ability to now successfully 
treat routine bacterial infections came what has become a major problem in 
health care;  anti-bacterial drug resistance.  Shortly after penicillin became widely 
used, there were reports of bacteria that were resistant to it.29  The mechanism of 
resistance to penicillin was derived from a β-lacatamase enzyme known as 
penicillinase which cleaved the lactam ring found in penicillin, leading to its 
inactivation.30  To combat penicillin resistant strains, a β-lacatamase resistant 
drug known as methicillin (Figure 7) was invented.31  Much like with penicillin,  
shortly after its introduction, S. aureus developed resistance to methicillin as well 
giving rise to what is now known as MRSA.32  
 
 
 
 
Figure 7:  Structure of Methicillin 
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Unlike the resistance of S. aureus to penicillin which stemmed from β-lacatamase 
enzymes, resistance to methicillin was derived via a novel penicillin binding 
protein.  Shown in Figure 8, in methicillin sensitive S. aureus (MSSA), the 
bacteria contains a set of four PBP's that act as transpeptidases that help with 
peptidoglycan synthesis.33,34  β-lactam antibiotics such as methicillin work by 
acetylating the active site serine and preventing these PBP's from acting as 
transpeptidases.35  
 
In MRSA, the bacteria acquire a fifth PBP that has a very low affinity for all β-
lactam antibiotics.  This 78 kDa PBP is known as PBP 2A can have a range of 
expression and production that can render S. aureus somewhat treatable to 
completely resistant to  β-lactam antibiotics.36,37,38  PBP 2A is encoded for by a 
gene known as mecA which is found on a mobile genetic element known as the 
staphylococcal cassette chromosome mec (SCCmec).39  The size of the 
SCCmec element ranges from 21-67 kb, depending on the variant.34  As of 2012, 
there are 11 known variants of the SCCmec, all of which contain the mecA gene, 
 
 
Figure 8:  Penicillin-binding protein (PBP) mechanism.  Figure adapted from 
reference 33. 
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which represents nearly a threefold increase in the number of variants from 
2004.31,40 
Ever since the first MRSA infection was discovered in 1961, the incidences of 
infection by MRSA have skyrocketed across the globe.41  Originally found mostly 
in Europe, in the 1980's, MRSA started to become a global epidemic.31  Due to 
the emergence of this global epidemic of MRSA infections, both in health care 
settings and in the community, there have been numerous surveillance programs 
set up to track MRSA infections. One such program is the SENTRY program 
which was initiated in 1997 to track the rates of antibacterial resistance over 
numerous pathogens.42  Shown in Figure 9 is some of the original data from the 
SENTRY program for MRSA.  In the United States, MRSA rates as high as 40% 
of nosocomial infections were noted between 1997 and 1999.43 
 
Figure 9:  Methicillin resistance rates in different regions around the globe 
from the SENTRY study between 1997-1999.  Figure adapted from reference 
43. 
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In 2003, the MRSA rate peaked at 64% in intensive care units in the United 
States.44  In 2005, the MRSA rate for non-nosocomial skin infections peaked at 
60%.45  With the incidences of MRSA rising at an alarming rate, the need to use 
non β-lactam antibiotics has risen with it.  As a result of this increased antibiotic 
use, some strains of MRSA have grown to be resistant to other classes of 
antibiotics such as the fluoroquinolones, tetracyclines, and aminoglycocides.46  
For this reason, the gold standard of treatment for MRSA infections has become 
vancomycin.32   
 
Shown in Figure 10, vancomycin was first approved for use in 1958 as a 
treatment for penicillin resistant S. aureus infections.47  Vancomycin is a 
glycopeptide antibiotic that exerts its antibacterial activity by inhibiting cell wall 
biosynthesis in a manner independent from the penicillin's.47,48  Due to advances 
in the development of novel antibiotics that were effective against S. aureus 
coupled with poor bioavailability and nephrotoxicity, vancomycin quickly fell out of 
 
Figure 10:  Structure of Vancomycin 
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use and it wasn't until MRSA started becoming resistant to multiple antibiotics 
that  vancomycin found widespread use again.47,49 
With vancomycin finding widespread use again to combat the most resistant 
strains of MRSA, given the history of S. aureus to develop drug resistance, it was 
not a big surprise that vancomycin-resistant strains of S. aureus started to 
emerge.  Research in the early 1990's showed that S. aureus can gain resistance 
to vancomycin through the transfer of the VanA gene of vancomycin resistant 
Enterococcus (VRE).50  With a major increase in the number of cases of VRE 
coupled with the ever growing number of cases of MRSA, the first case of 
vancomycin resistant S. aureus (VRSA) was documented in 1997.51  However 
this case of VRSA was not due to the presence of the VanA gene, it was due to 
the bacteria growing a thicker cell wall that prevents vancomycin from interacting 
with its cellular target.52,53  It was not until 2002 that the first documented case of 
VRSA containing the VanA gene transferred from VRE showed up, proving this 
gene transfer could occur in vivo.54,55   
With the likelihood of more cases of MRSA becoming resistant to vancomycin, 
there are a number of other antibacterial agents that are either approved or in 
trials currently.  Shown in Figure 11 are four of those agents.  Ceftaroline is a 
cephalosporin with broad-spectrum activity that has been approved for use in 
skin infections caused by MRSA in the United States.56,57  Tigecycline is a 
glycylcycline antibiotic that is bacteriostatic and approved in the United states 
and Europe for skin infections, intra-abdominal infections, and community-
acquired pneumonia.56,58  Trimethoprim is a dihydrofolate reducatase (DHFR) 
14 
 
inhibitor that is used in cases of milder skin infections caused by MRSA.56,59  
Linezolid is a oxazolidinone antibiotic used in pneumonia and bacteremia caused 
by MRSA.56,60  Not shown in the figure are telavancin which is a lipoglycopeptide 
antibiotic that is approved in the United States and used only in severe cases 
due to its high toxicity.56,61  Daptomycin is a lipopeptide approved in Europe for 
skin infections, however it is not effective in cases of pneumonia caused by 
MRSA.56,62 
 
 
 
 
 
 
Figure 11:  Other drugs used to treat MRSA.  Ceftaroline (cephalosporin), 
tigecycline (glycylcycline), trimethoprim (DHFR inhibitor), and linezolid 
(oxazolidinone). 
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Vancomycin Resistant Enterococcus (VRE) 
The first infection caused by Vancomycin Resistant Enterococcus (VRE) was first 
reported in 1986 in a hospital in England.63  Only 5 years after the first reported 
case in England, VRE was reported in New York City hospitals.64  By the year 
2000, the CDC was reporting that 26% of all enterococcus infections in intensive 
care units were resistant to vancomycin.65  For blood stream infections, the 
number caused by VRE skyrocketed to almost 81% in 2010.66  Normally, 
Enterococci are benign inhabitants of the gut flora that only cause infections in 
cases where there is a confounding illness.  Enterococci infections are caused 
primarily by two species, E. faecium and E. faecalis.67  Out of these two species, 
vancomycin resistant strains are far more prevalent in E. faecium than in E. 
faecalis.68   
Resistance of Enterococci to vancomycin is derived from modifications of the 
peptidoglycan synthetic pathway in the bacterial cell wall.  Unlike in MRSA, 
resistance is not derived from a novel protein that has low affinity for the drugs 
but is derived from modification of the pieces that comprise the cell wall itself.69  
In normal cell wall biosynthesis, a dipeptide comprised of D-Ala-D-Ala is part of 
the pathway and is also the target for vancomycin and other glycopeptide 
antibiotics.66  Resistant strains have several different Van genes including; VanA, 
VanB, and VanD that encode for a depsipeptide D-Ala-D-Lactate instead of the 
native D-Ala-D-Ala.70  By changing to D-Ala-D-Lac, a key hydrogen bond is 
removed in the interaction between the target and vancomycin which leads to a 
1000-fold decrease in affinity which causes the resistance to vancomycin.71 
16 
 
With an increase in incidents of infections by VRE that are also resistant to β-
lactam antibiotics, there have only been two new therapies approved for the 
treatment of VRE infections in the early 2000s.66 
 
Dalfopristin-Quinupristin (Figure 12) is a mixture of the two drugs belonging to 
the streptogramin class in a 70:30 ratio respectively.72  The major drawback of 
this treatment and the main reason why it is no longer used, despite good activity 
against VRE, is the fact that it requires a central IV line to administer.66  The 
other recently approved drug is linezolid.  With excellent oral bioavailability and 
broad spectrum activity against most gram-positive bacteria, including VRE, it 
has become the front line antibacterial drug for the treatment of VRE.73 
 
 
 
 
 
Figure 12:  Structures of Dalfopristin (left) and Quinupristin (right) 
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Acinetobacter Baumannii (A. Baumannii) 
Acinetobacter Baumannii is a gram-negative, non-fermentative coccobacillus that 
is responsible for a wide range of human infections.74  Drug resistant A. 
baumannii was first discovered in the 1970's.  While A. baumannii infections are 
normally associated with health care settings, there have been some reports of 
community associated infections starting in the early 2000's.75  Multi-drug 
resistant A. baumannii is resistant to any combination of carbapenems, 
cephalosporins, ampicillin-sulbactam, aminoglycocides, and fluoroquinolones.76 
Unlike MRSA and VRE, which derive their resistance through a small set of 
specific enzymes or mutations, multi-drug resistant A. baumannii has a wide 
array of resistant mechanisms at its disposal for each class of antibiotic drugs.  
The main resistance mechanism used against β-lactams are β-lacatamase and 
cephalosporinases that enzymatically degrade the drugs before they can 
acetylate their respective targets.77  To a lesser degree, β-lactam resistance is 
also conferred via a lower membrane permeability in A. baumannii than in other 
micro-organisms.78   
Resistance to aminoglycocides is caused by two separate mechanisms, the first 
is enzymatic inactivation of the drug and the second and less prominent is efflux 
pumps.79  Aminoglycocide resistant A. baumannii is caused primarily by the 
expression of acetyletransferases, adenyltransferases, and phosphotransferases 
that inactivate the drug before it can bind its target.80   
Fluoroquinolones exert their antibacterial action by binding to either DNA gyrase 
or bacterial topoisomerase IV.81  In gram negative bacteria such as A. baumannii, 
18 
 
DNA gyrase is the primary target for the fluoroquinolones.  DNA gyrase is 
primarily encoded by two different genes, gyrA and gyrB.  It was found that 
specific mutations in the gyrA gene changed the binding site for the 
fluoroquinolones which vastly decreased their affinity for DNA gyrase and 
conferred resistance to them.82 
With several resistance mechanisms available for the majority of commonly used 
antibiotic agents, options are becoming limited in cases of multi-drug resistant A. 
baumannii.  In cases where there is little to no resistance, the front line treatment 
for infections caused by A. baumannii is members of the carbapenem class of 
antibiotics.83    In cases where the infection is caused by a multi-drug resistant 
strain, practitioners have turned to polymyxin B which is a cationic polypeptide 
with normally excellent activity against gram-negative bacteria.83,84  Despite its 
excellent activity, due to growing use, a strain of polymyxin B resistant A. 
baumannii was isolated in 2001 which is cause for great concern due to the 
polymyxins being a drug of last resort due to its high toxicity.84  Tetracyclines and 
glycylcyclines are another class of antibiotics that are used to treat resistant A. 
baumannii infections.83  However, as with the polymyxins and other previously 
discussed classes of antibacterial drugs, resistance to tetracyclines and 
tigecycline has cropped up in 200385 and 200786 respectively.   
As can be seen by the many mechanisms of resistance not only in A. baumannii 
but in MRSA and VRE as well, that there is a pressing need for novel antibiotics 
that either bypass current resistance mechanisms or act via novel mechanisms 
or on novel targets. 
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Chapter 3:  Synthesis and Evaluation of 9-alkylaminoacridines with Activity 
Against Methicillin-Resistant Staphylococcus aureus (MRSA)  
Abstract 
Introduction 
Staphylococcus aureus is one of the leading causes of bacterial infections in 
humans with symptoms ranging from simple skin infections to severe necrotizing 
pneumonia.87,88  Methicillin-resistant Staphylococcus aureus (MRSA) was first 
discovered in 1961, shortly after the introduction of methicillin.89 Originally, 
infection by MRSA was limited to those exposed in health care settings.90   In 
1981, it was first reported that MRSA infections have spread to the community 
and are currently the leading cause of soft tissue and skin infections today not 
only in the community but also in the clinic.91,92  
Vancomycin is currently the first choice of antibiotic to treat MRSA infections.93  
However due to the increased use of vancomycin, a situation described as MIC 
“creep” has been occurring in which more strains of MRSA are requiring higher 
doses to successfully treat the infection.94  This upward trend of MIC’s against 
certain strains of MRSA is leading to the development of moderately to highly 
vancomycin resistant strains.56  In cases where vancomycin fails, the next line of 
treatment generally involves linezolid, ceftaroline, or telavancin.95,96  
Telavancin is a semi-synthetic derivative of vancomycin.97  Telavancin has 
superior activity to vancomycin due to its dual mechanism of action.  Telavancin 
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both inhibits cell wall biosynthesis like traditional glycopeptide antibiotics as well 
as disrupts the cell membrane by anchoring itself via a lipophilic side chain.61  
Despite the advances in treating MRSA with telavancin, there still remains a 
major need to develop newer and more effective antibiotics to treat ever evolving 
drug resistant bacteria. 
One potential source of novel antibacterial agents goes back to some of the 
original antibacterial agents to be used, the aminoacridines.  Acridines, originally 
only used as dyes, were tested in the late 1800’s to early 1900’s and found to 
have antibacterial activity.  Originally used extensively for the treatment of 
wounds during the First World War, the acridines fell out of favor until they were 
re-examined for use in wounds during the Second World War.  This led to the 
widespread use of Aminacrine (9-aminoacridine) in wounds where other 
treatments had failed.98  The use of acridines as antibacterial agents occurred up 
until penicillin became more widely available.99  
Research by Albert and Goldacre showed that acridines that exist primarily as 
cations at physiological pH are the best antibacterial agents.  Further research 
into the structural features that gave acridines and other heterocyclic bases 
antibacterial properties also showed that a large planar surface area is also a key 
feature, as highly ionized aminoquinolines and aminopyridines did not show any 
activity in antibacterial assays.100  Knowing the flat planar surface area was a key 
feature, it was determined in 1963 that acridines act on the level of the DNA via 
intercalating between the base pairs.101  It was shown that the intercalation of the 
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acridine into the DNA disrupts the action of DNA topoisomerases, leading to cell 
death.102 
Herein we report the synthesis and evaluation of three series of acridine and 
acridone based compounds bearing an alkylamino moiety of varying length.  To 
fully probe the effect of the 9-amino substituent, two series of acridines with a 9-
aklyamino moiety ranging from three to sixteen carbons were synthesized.  As a 
non-intercalative control, a series of acridones bearing the same alkylamine 
moieties was synthesized.  All compounds were tested in two strains of MRSA 
and one strain of methicillin-sensitive Staphylococcus aureus (MSSA).  All of the 
acridine based compounds were also tested against the DU145 prostate cancer 
cell line as a general measure of cytotoxicity.  In the case of acridines, an active 
and non-active compound along with the analogous acridones was tested in a 
DNA intercalation assay as well to explore their mechanism of action.    
Synthesis 
Two different routes were used to make 2-phenylaminoterephthalic acid 5.  The 
first route followed a previous published literature procedure.103  Due to variable 
yields which were often low using the modified Ullmann-Goldberg coupling, a 
second and higher yielding route was used to provide the intermediate for the 3-
carboxamide substituted acridines.  Shown in Scheme 1 is the second route 
which provided a route with consistently high yields of the desired coupling 
product 5.  2-iodoterephthalic acid 2 was synthesized from 2-aminoterephthalic 
acid 1 via a Sandmeyer reaction.104  Dimethyl-2-iodoterephthalate 3 was 
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synthesized by reacting 2 with methyl iodide in DMF using potassium carbonate 
as the base.  Dimethyl-2-iodoterephthalate was coupled with aniline using a 
Buchwald-Hartwig amination reaction with subsequent saponification of the 
esters with sodium hydroxide to afford 2-phenylaminoterephthalic acid 5.7 
Cyclization to give the 9-chloroacridines was accomplished by refluxing 5 in 
phosphorous oxychloride.  In the case of the acridines with no substitution at the 
3-position, commercially available 2-phenylanthranillic acid 6 was used instead.  
The unstable 9-chloro derivatives were converted to stable 9-phenoxy derivatives 
by reacting with excess phenol.  To complete the synthesis of the two series of 9-
aminoacridines, the respective 9-phenoxyacridne was reacted with the 
appropriate alkylamine to yield the desired 9-alkylamino acridines. 
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The control series of 3-carboxamide acridones was synthesized following the 
route outlined in Scheme 2.  5 was cyclized in polyphosphoric acid to give the 
acridone acid 10.  BOP-Cl and triethylamine was used to couple 10 with each 
respective amine in DMF to afford the 3-carboxamide acridone series 11.105  
 
 
Scheme 2:  Synthesis of 3-carboxamide acridone compounds.  Reagents and 
conditions:  (a) PPA, 145° C; (b) amine, BOP-Cl, Et3N, DMF, rt. 
 
 
Scheme 1:  Synthesis of 9-aminoacridine compounds.  Reagents and 
conditions:  (a) i. NaNO2, ii. KI, 1:1 HCl:H2O, rt; (b) MeI, K2CO3, DMF, rt.; (c) 
Pd(OAc)2, dppf, Cs2CO3, toluene, 95° C; (d) 5% NaOH, acetone, rt; (e) (i) 
POCl3, reflux, (ii) Amine, DCM, rt; (f) phenol, 80° C; (g) amine, phenol, 50-100° 
C. 
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Results and Discussion 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Compound R1 n 
ATCC 
43300 
IRDL 
6169 
IRDL 
8545 DU145 
9a H 2 >100 >100 >100 4.76 ± 0.35 
9b H 3 >100 >100 >100 5.01 ± 1.00 
9c H 4 >100 >100 >100 4.55 ± 0.46 
9d H 5 50.58 46.88 >100 5.43 ± 0.67 
9e H 6 24.49 22.86 27.54 5.53 ± 0.83 
9f H 7 8.54 10.79 10.26 5.80 ± 1.17 
9g H 8 3.19 3.59 5.95 6.55 ± 0.78 
9h H 9 2.19 3.29 2.61 6.46 ± 0.28 
9i H 10 2.01 2.73 3.81 6.12 ± 0.32 
9j H 11 2.88 2.73 2.88 5.90 ± 0.62 
9k H 12 3.04 2.80 2.61 5.41 ± 0.75 
9l H 13 3.07 2.15 2.98 5.15 ± 0.41 
9m H 14 6.10 3.21 5.69 4.88 ± 0.64 
9n H 15 24.72 10.14 26.24 4.81 ± 0.74 
9o N-methylpiperazinyl 2 >100 >100 >100 >200 
9p N-methylpiperazinyl 3 >100 >100 >100 83.81 ± 6.90 
9q N-methylpiperazinyl 4 >100 >100 >100 101.18 ± 57.00 
9r N-methylpiperazinyl 5 >100 >100 >100 28.48 ± 2.62 
9s N-methylpiperazinyl 6 >100 >100 >100 19.13 ± 6.76 
9t N-methylpiperazinyl 7 >100 >100 >100 14.22 ± 3.68 
9u N-methylpiperazinyl 8 22.70 23.66 35.48 6.42 ± 1.29 
9v N-methylpiperazinyl 9 12.16 10.74 11.97 5.23 ± 0.54 
9w N-methylpiperazinyl 10 3.61 6.14 6.23 2.52 ± 0.82 
9x N-methylpiperazinyl 11 6.28 5.87 4.80 2.04 ± 1.28 
9y N-methylpiperazinyl 12 2.91 3.07 3.57 2.72 ± 0.62 
9z N-methylpiperazinyl 13 5.82 6.13 6.25 2.76 ± 0.28 
9aa N-methylpiperazinyl 14 4.59 8.59 5.91 3.50 ± 0.91 
9bb N-methylpiperazinyl 15 6.23 9.06 11.59 3.52 ± 1.38 
11a-n - 2-15 >100 >100 >100 ND 
Table 1:  Anti-bacterial assay results for MRSA (ATCC43300 and IRDL6169) 
and MSSA (IRDL8545) and prostate cancer cytotoxicity.  Anti-bacterial data is 
MIC99 (µM), anti-cancer data is EC50 (µM).   
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Anti-bacterial activities (MIC99) and 
for the two series of acridines and 
one series of acridones is reported in 
Table 1.    Compounds were tested in 
two strains of MRSA and one strain of 
MSSA.  In the two series of acridines, 
both showed antibacterial activity to 
be tied to the length of the 9-
aklylamino substituent.  Shown in 
Table 1, the un-substituted acridines 
19a-19n, antibacterial activity was 
first exhibited when the 9-amino 
substituent reached six carbons and 
reached max potency when the 9-
amino substituent reaches ten 
carbons with no further increase in 
activity.  In the case of the 3-
carboxamide substituted acridines 19o-19bb, antibacterial activity was first 
exhibited when the 9-amino substituent reached nine carbons and reached peak 
activity at thirteen carbons with no increase in activity after that length.  In the 
case of both the un-substituted and substituted acridines, the max potency did 
not differ significantly (graphically represented in Figure 13).   In each series, 
there was no discernible difference in activity between the resistant and sensitive 
 
Figure 13:  MIC vs. alkylamino length 
for the three cell lines tested. 
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S. aureus, which suggests that there is no selectivity in these compounds for 
resistant strains.  
Also shown in Table 1 is the cytotoxicity data for the two series of acridines in the 
DU145 prostate cancer cell line.  In the case of the un-substituted acridines (9a-
9n) cytotoxicity was not linked to the length of the alkylamino substituent like it 
was in the case of the anti-bacterial activities.  These compounds all exhibited a 
relatively high degree of cytotoxicity across the entire series (~5 µM) whereas the 
3-carboxamide substituted acridines cytotoxicity depended on the length of the 9-
alkylamino substituent in a nearly identical trend as the anti-bacterial activity. 
As a control, we also synthesized a series of acridones bearing the alkylamine 
attached via a 3-carboxamide linker.  Shown in Table 1 is the anti-bacterial 
activity for the series of acridones, 11a-11n.  None of the acridones tested 
showed any activity at 100 µM.  This result was as expected given the acridones 
were designed to be neutral at physiological pH and previous testing in our 
laboratory on similar compounds showed that 3-carboxamide substituted 
acridones are poor DNA intercalators.103  Lacking both of these features that the 
9-alkylamino acridines contain, along with lacking any anti-bacterial activity, this 
is strong evidence that the anti-bacterial activity of the acridines is derived from a 
combination of both carbon chain length and the ability to exist as a cation under 
physiological conditions rather than just by the length of the carbon chain of the 
substituent. 
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Given our data shows that the antibacterial activity of the acridine compounds is 
driven by the length of the 9-amino substituent, we tested both an active and 
inactive compound from each series along with analogous acridone controls in a 
DNA intercalation assay to determine if these compounds are acting via multiple 
mechanisms.  Shown in Figure 14 are the DNA intercalation assays for the six 
compounds tested.  In this assay, relaxed DNA becomes supercoiled when a 
compound intercalates into DNA.106  Surprisingly, compounds 9a and 9o, 
corresponding to the two propyl analogs which show no anti-bacterial activity 
show the highest degree of intercalation.  Compounds 9h and 9v, which 
correspond to the active decyl compounds, show very weak intercalation.  As 
expected from previous work on similar compounds, neither compound 11a or 
11h showed that the intercalated DNA.   
 
 
 
 
Figure 14:  DNA intercalation assay.   
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Conclusions 
This study has examined two series of 9-alkylamino acridines and a series of 3-
carboxamide acridones.  In the case of both the un-substituted and 3-
carboxamide substituted acridines, anti-bacterial activity increased with the 
length of the alkylamino substituent at the 9 position at different rates but 
reaching similar peak values.  None of the 3-carboxamide substituted acridones 
showed any anti-bacterial activity in the cell lines tested.   
In an attempt to elucidate the mechanism of action of the acridine compounds, a 
DNA intercalation assay was run as acridines are well known to intercalate into 
DNA and interfere with replication.101,107,108  Seen in Figure 13 is the data for the 
intercalation assay in which contrary to expected, the non active acridines 
showed the highest degree of intercalation.  Some of the most active compound 
(9h and 9v) show very low levels of intercalation, even at high concentration.  
This is somewhat surprising though not unprecedented.  In a previous study, 
Galy and co-workers showed that increasing the length of an alkylamine at the 9 
position of an acridine increased its affinity for DNA until the length reaches 6 
carbons long.  After that length, any increase in additional length led to a 
decrease in affinity for DNA.108  Given our compounds started showing activity 
around the length of alkylamino substituent that lead to a decrease in DNA 
intercalation, this led us to look into an alternative mechanism of action for our 
compounds.   
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Since the most active acridines are likely not 
acting through a mechanism that involves DNA 
intercalation, we propose that they are instead 
killing the bacteria by membrane disruption.  
The bacterial cell membrane contains a higher 
percentage of negative charges with allows for compounds that contain a positive 
charge to interact with them.109,110  This ionic interaction and subsequent 
membrane disruption is what gives quaternary ammonium compounds,111 
cationic anti-microbial peptides,112 and cationic amphiphiles109 their anti-bacterial 
properties.  Given 9-aminoacridnes have a pKa around 9-10 they would be 
protinated at physiological pH.98,113  Shown in Figure 15 are the two possible 
tautomers of a 9-alkylamino acridine.  Given the longer and more hydrophobic 
alkyls are the most active, we believe these acridines are acting in a similar 
fashion as cationic amphiphiles, disrupting the bacterial cell membrane, and 
leading to bacterial death.  This mechanism could be advantageous as it is does 
not hit a specific target, meaning it could be harder for the bacteria to develop 
new resistance to these compounds via modification of the target.   
Despite the good anti-bacterial activity of the most active compounds, the most 
active compounds also showed high levels of cytotoxicity, which would hinder 
their use.  Future work on these compounds would involve performing membrane 
disruption assays to confirm the mechanism of action.  Also, fine tuning the 
properties of these 9-alkylamino acridines to allow them to maintain their anti-
Figure 15:  Two possible 
tautomers of the protinated 
acridine. 
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bacterial activity while cutting down on their cytotoxicity could lead to new anti-
bacterial compounds to treat up and coming drug resistant bacteria. 
Experimental 
Anti-bacterial assay (broth micro dilution) 
 Compounds were tested against Methicillin-resistant Staphylococcus aureus 
(MRSA) purchased from the American Type Culture Collection (ATCC):  ATCC 
43300.  Two clinical isolates of S. aureus (MRSA: IDRL 6169 and MSSA: IDRL 
8545) were also tested. S. aureus was grown in BBLTM TrypticaseTM Soy Broth 
(BD) at 37 °C.  
Microbial susceptibility testing was performed using an adaptation of the 
standard broth micro dilution assay.114  Briefly, bacteria were grown to mid-log 
phase, diluted with fresh medium to an optical density at 600 nm (OD600) of 
0.030-0.060 and then diluted again 1:10.  This suspension (195 µL) was added to 
wells in a 96 well microtiter plate (Sarstedt) and 5 µL of compound dissolved in 
DMSO was added to give a final concentration of 100 – 0.1 µM at 2.5% DMSO 
by volume. A DMSO negative control and standard antibiotic positive controls 
were included in each plate. All compounds were tested in triplicate for each 
concentration. Plates were sealed with parafilm, placed in a Ziploc bag to prevent 
evaporation, and incubated at 37 °C for 16-20 hours.  The OD600 values for each 
well were determined with a plate reader (Biotek, EL800) and the data were 
standardized to the DMSO control wells.  Initial single concentrations were tested 
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at 100 µM and active compounds were further tested with at least nine 
concentrations for a full dose response.  Dose response curves were generated 
using GraphPad Prism 4 software and used to determine the MIC99 
concentrations (minimal concentration that inhibits 99% of growth). 
DNA intercalation assay 
A DNA intercalation assay was performed as described previously.115  Briefly, 
reaction mixtures (20 l) containing 50 mM Tris-HCl (pH 7.5 at 23C), 2.5 mM 
MgCl2, 0.5 mM DTT, 50 g/ml BSA, 300 ng of relaxed plasmid DNA, and 2 units 
of human topoisomerase I (Topogen, Port Orange, Fl) were incubated at 37 °C 
for 10 min in the absence or presence of the indicated concentrations of the 
various compounds.  Reactions were terminated by extraction with 
phenol/chloroform/isoamyl alcohol (25:24:1, v/v) and the DNA products were 
analyzed by electrophoresis through vertical 1.2% SeaKem ME agarose (Lonza, 
Rockland, ME) gels (14 x 10 x 0.3 cm) at 2 V/cm for 15 h in TAE buffer [50 mM 
Tris-HCl (pH 7.9 at 23 oC), 40 mM sodium acetate and 1 mM EDTA]. Gels were 
stained with ethidium bromide and photographed using a Stratagene Eagle Eye 
gel documentation system (Agilent Technologies, Santa Clara, CA). 
Cell Titer Blue cytotoxicity assay 
DU145 cells were cultured in RPMI-1640 media supplemented with 10% fetal 
bovine serum (FBS) and 1% penicillin/streptomycin (pen/strep).  After reaching 
confluency, cells were treated with trypsin, pelletized, and re-suspended in 
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growth media.  Cell concentration was determined via counting on a 
hemocytometer and then cells were plated at a concentration of 5000 cells per 
well and left to incubate for 24 hours.  After 24 hours, growth media was removed 
and the cells were treated with fresh growth media containing 2% DMSO and the 
compounds starting at 100 µM with a 2-fold dilution factor over 8 wells in 
triplicate.  The treated cells were incubated for 48 hours then viability was tested 
using the Cell Titer-Blue® assay.  Dose response curves and EC50 values were 
calculated using GraphPad Prism 4.0.  The assays were repeated on three 
consecutive days. 
Chemistry General 
2-iodoterephthalic acid (2):  This compound was prepared from 2-
aminoterephthalic acid via a Sandmeyer reaction according to the conditions 
previously published.104  74% yield.  
Dimethyl-2-iodoterephthalate (3):  2-iodoterephthalic acid (5.56 mmol) was 
dissolved in DMF and 2.2 equivalents of K2CO3 (12.23 mmol) were added and 
the reaction was stirred at room temperature for 30 min.  After 30 min, 2.2 
equivalents of methyl iodide (12.23 mmol) were added drop wise and the 
reaction was stirred another 1 hour at room temperature.  The reaction mixture 
was taken into 600 mL of Et2O and washed 3x 350 mL of water to remove salts 
and DMF.  Concentration of the organic layer yielded 16.24g (5.07 mmol) of 
yellow solid.  91% yield.  1H NMR (400 MHz, CDCl3) δ 3.94 (s, 3H), 3.96 (s, 3H), 
7.80 (d, J = 8.2 Hz, 1H), 8.04 (dd, J = 8.1, 1.7 Hz, 1H), 8.62 (d, J = 1.2 Hz, 1H). 
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Dimethyl-(2-phenylamino)terephthalate (4):  Compound was prepared by a 
modified procedure found in the literature.7  Pd(OAc)2 (3 mol%), dpff (6 mol%) 
and aniline (60 mmol) were dissolved in 125 mL dry toluene and stirred under 
argon at 95° C for 15 min.  After 15 min, dimethyl-2-iodoterephthalate (50 mmol) 
and Cs2CO3 (70 mmol) were added.  The reaction mixture was stirred at 95 °C 
for 10 hours.  After cooling, the reaction was filtered and concentrated in vacuo.  
The resultant oil was adsorbed on celite and purified on silica eluting 10% 
EtOAc:Hexanes to 20% EtOAc:Hexanes to afford 13.5g (47.32 mmol) of yellow 
solid.  95% yield.  1H NMR (400 MHz, CDCl3) δ 3.87 (s, 3H), 3.93 (s, 3H), 7.13 
(m, 1H), 7.25 (m, 2H), 7.35 (m, 3H), 7.91, (s, 1H), 8.01 (d, J= 8.4 Hz, 1H), 9.5 (s, 
1H). 
2-aminoterephthalic acid (5):  Dimethyl-(2-phenylamino)terephthalate (47.32 
mmol) was dissolved in 500 mL of acetone.  350 mL of 5% NaOH was added 
and the reaction was stirred at room temperature overnight.  The reaction was 
then neutralized with 3N HCl and the organics were removed under reduced 
pressure.  The resultant yellow solid was collected via filtration and washed 2x 
with 150mL water to yield 10.9g (42.37 mmol) of yellow solid.  90% yield.  1H 
NMR (400 MHz, DMSO-d6) δ 7.14 (m, 1H), 7.28 (m, 3H), 7.40 (m, 2H), 7.74 (s, 
1H), 7.98 (d, J= 8.2 Hz, 1H), 9.61 (s, 1H), 13.25 (br, s, 2H); HRMS (C14H12N2). 
General Procedure for 9-chloroacridine (7) and 9-phenoxyacridine (8):  
Previously published procedures were followed for the synthesis of these 
compounds.103 
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General Procedure for Compounds 9a-9n:   
 9-propylamino-acridine (9a).  9-phenoxy-acridine (0.5 mmol) was added 
to a round bottomed flask with 1.0 g of phenol.  Propylamine (1.0 mmol) was 
added and the reaction was stirred at 100 °C for 1 hour.  Upon cooling, the 
reaction was diluted in CH2Cl2 and purified on silica eluting 90:10 CH2Cl2:MeOH 
to 85:10:5 CH2Cl2:MeOH:Et3N.  The fractions containing the product were 
concentrated and placed under high vacuum where the product solidified as a 
yellow solid.  Yield:  31%; 1H NMR (600 MHz, CD3OD) δ 1.08 (t, J = 7.3 Hz, 3H), 
2.015 (sextet, J = 7.3 Hz, 2H), 4.12 (t, J = 7.3 Hz, 2H), 7.56 (t, J = 7.9 Hz, 2H), 
7.81 (d, J = 8.5 Hz, 2H), 7.96 (t, J = 7.9 Hz, 2H), 8.50 (d, J = 8.5, 2H); HRMS 
(C16H17N2) [M+H]+:  found m/z 237.1392, calcd 237.1386. 
 9-butylamino-acridine (9b).  Yield:  22%; 1H NMR (600 MHz, CD3OD) δ 
1.01 (t, J = 7.3 Hz, 3H), 1.515 (sextet, J = 7.3 Hz, 2H), 1.97 (pentet, J = 7.6 Hz, 
2H), 4.15 (t, J = 7.3 Hz, 2H), 7.55 (t, J = 7.9 Hz, 2H), 7.805 (d, J = 8.5 Hz, 2H), 
7.95 (t, J = 7.9 Hz, 2H), 8.495 (d, J = 8.8 Hz, 2H); HRMS (C17H19N2) [M+H]+:  
found m/z 251.1547, calcd 251.1543. 
 9-pentylamino-acridine (9c).  Yield:  28%; 1H NMR (600 MHz, CD3OD) δ 
0.95 (t, J = 7.3 Hz, 3H), 1.39-1.49 (m, 4H), 1.99 (pentet, J = 7.6 Hz, 2H), 4.15 (t, 
J = 7.3 Hz, 2H), 7.56 (t, J = 7.9, 2H), 7.81 (d, J = 8.5 Hz, 2H), 7.96 (t, J = 7.9 Hz, 
2H), 8.50 (d, J = 8.5 Hz, 2H); HRMS (C18H21N2) [M+H]+:  found m/z 265.1702, 
calcd 265.1699. 
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 9-hexylamino-acridine (9d).  Yield:  72%; 1H NMR (600 MHz, CD3OD) δ 
0.89 (t, J = 7.3 Hz, 3H), 1.31-1.39 (m, 4H), 1.47 (m, 2H), 1.97 (pentet, J = 7.6 Hz, 
2H), 4.12 (t, J = 7.3 Hz, 2H), 7.54 (t, J = 7.9 Hz, 2H), 7.795 (d, J = 8.2 Hz, 2H), 
7.93 (t, J = 7.9 Hz, 2H), 8.47 (d, J = 8.5 Hz, 2H); HRMS (C19H23N2) [M+H]+:  
found m/z 279.1859, calcd 279.1856. 
 9-heptylamino-acridine (9e).  Yield:  19%; 1H NMR (600 MHz, CD3OD) δ 
0.88 (t, J = 6.5 Hz, 3H), 1.30-1.31 (m, 4H), 1.38-1.40 (m, 2H), 1.47 (pentet, J = 
7.6 Hz, 2H), 1.98 (pentet, J = 7.6 Hz, 2H), 4.15 (t, J = 7.3 Hz, 2H), 7.56 (t, J = 7.6 
Hz, 2H), 7.81 (d, J = 8.5 Hz, 2H), 7.96 (t, J = 7.6 Hz, 2H), 8.50 (d, J = 8.5 Hz, 
2H); HRMS (C20H25N2) [M+H]+:  found m/z 293.2006, calcd 293.2012. 
 9-octylamino-acridine (9f).  Yield:  18%; 1H NMR (600 MHz, CD3OD) δ 
0.87 (t, 7.0 Hz, 3H), 1.22-1.40 (m, 8H), 1.47 (pentet, J = 7.6 Hz, 2H), 1.98 
(pentet, J = 7.6 Hz, 2H), 4.15 (t, J = 7.3 Hz, 2H), 7.56 (t, J = 7.9 Hz, 2H), 7.81 (d, 
J = 8.5 Hz, 2H), 7.96 (t, J = 7.9 Hz, 2H), 8.495 (d, J = 8.8 Hz, 2H); HRMS 
(C21H27N2) [M+H]+:  found m/z 307.2161, calcd 307.2169. 
 9-nonylamino-acridine (9g).  Yield:  51%; 1H NMR (600 MHz, CD3OD) δ 
0.87 (t, J = 7.0 Hz, 3H), 1.22-1.33 (m, 8H), 1.35-1.40 (m, 2H), 1.47 (pentet, J = 
7.6 Hz, 2H), 1.98 (pentet, J = 7.6 Hz, 2H), 4.14 (t, J = 7.3 Hz, 2H), 7.55 (t, J = 8.2 
Hz, 2H), 7.815 (d, J = 8.5 Hz, 2H), 7.95 (t, J = 8.2 Hz, 2H), 8.49 (d, J = 8.8 Hz, 
2H); HRMS (C22H29N2) [M+H]+:  found m/z 321.2322, calcd 321.2325. 
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 9-decylamino-acridine (9h).  Yield:  33%; 1H NMR (600 MHz, CD3OD) δ 
0.88 (t, J = 7.3 Hz, 3H), 1.21-1.34 (br, m, 10H), 1.38 (pentet, J = 7.6 Hz, 2H), 
1.47 (pentet, J = 7.6 Hz, 2H), 1.98 (pentet, J = 7.6 Hz, 2H), 4.15 (t, J = 7.3 Hz, 
2H), 7.56 (t, J = 7.9 Hz, 2H), 7.81 (d, J = 8.5 Hz, 2H), 7.96 (t, J = 7.9 Hz, 2H), 
8.50 (d, J = 8.5 Hz, 2H); HRMS (C23H31N2) [M+H]+:  found m/z 335.2482, calcd 
335.2482. 
 9-undecylamino-acridine (9i).  Yield:  37%; 1H NMR (600 MHz, CD3OD) 
δ 0.88 (t, J = 7.3 Hz, 3H), 1.21-1.34 (br, m, 12H), 1.34-1.41 (m, 2H), 1.47 (pentet, 
J = 7.6 Hz, 2H), 1.98 (pentet, J = 7.6 Hz, 2H), 4.15 (t, J = 7.3 Hz, 2H), 7.56 (t, J = 
7.6 Hz, 2H), 7.81 (d, J = 8.5 Hz, 2H), 7.96 (t, J = 7.9 Hz, 2H), 8.50 (d, J = 8.5 Hz, 
2H); HRMS (C24H33N2) [M+H]+:  found m/z 349.2629, calcd 349.2638. 
 9-dodecylamino-acridine (9j).  Yield:  20%; 1H NMR (600 MHz, CD3OD) 
δ 0.88 (t, J = 7.3 Hz, 3H), 1.22-1.34 (br, m, 14H), 1.38 (pentet, J = 7.6 Hz, 2H), 
1.47 (pentet, J = 7.6 Hz, 2H), 1.98 (pentet, J = 7.6 Hz, 2H), 4.14 (t, J = 7.3 Hz, 
2H), 7.55 (t, J = 7.9 Hz, 2H), 7.81 (d, J = 8.5 Hz, 2H), 7.95 (t, J = 7.3 Hz, 2H), 
8.495 (d, J = 8.8 Hz, 2H); HRMS (C25H35N2) [M+H]+:  found m/z 363.2785, calcd 
363.2795. 
 9-tridecylamino-acridine (9k).  Yield:  48%; 1H NMR (600 MHz, CD3OD) 
δ 0.88 (t, J = 7.0 Hz, 3H), 1.22-1.34 (br, m, 16H), 1.34-1.41 (m, 2H), 1.48 (pentet, 
J = 7.6 Hz, 2H), 1.98 (pentet, J = 7.6 Hz, 2H), 4.15 (t, J = 7.3 Hz, 2H), 7.57 (t, J = 
7.3 Hz, 2H), 7.81 (d, J = 8.5 Hz, 2H), 7.96 (t, J = 7.6 Hz, 2H), 8.50 (d, J = 8.8 Hz, 
2H); HRMS (C26H37N2) [M+H]+:  found m/z 377.2937, calcd 377.2951. 
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 9-tetradecylamino-acridine (9l).  Yield:  28%; 1H NMR (600 MHz, 
CD3OD) δ 0.88 (t, J = 7.0 Hz, 3H), 1.21-1.34 (br, m, 18H), 1.34-1.41 (m, 2H), 
1.43-1.51 (m, 2H), 1.98 (pentet, J = 7.6 Hz, 2H), 4.14 (t, J = 7.0 Hz, 2H), 7.55 (t, 
J = 7.6 Hz, 2H), 7.81 (d, J = 8.5 Hz, 2H), 7.95 (t, J = 7.6 Hz, 2H), 8.495 (d, J = 
8.5, 2H); HRMS (C27H39N2) [M+H]+:  found m/z 391.3096, calcd 391.3108. 
 9-pentadecylamino-acridine (9m).  Yield:  67%; 1H NMR (600 MHz, 
CD3OD) δ 0.88 (t, J = 7.3 Hz, 3H), 1.22-1.34 (br, m, 20H), 1.38 (pentet, J = 7.3 
Hz, 2H), 1.47 (pentet, J = 7.6 Hz, 2H), 1.98 (pentet, J = 7.3 Hz, 2H), 4.14 (t, J = 
7.3 Hz, 2H), 7.56 (t, J = 7.9 Hz, 2H), 7.81 (d, J = 8.5 Hz, 2H), 7.95 (t, J = 7.9 Hz, 
2H), 8.495 (d, J = 8.8 Hz, 2H); HRMS (C28H41N2) [M+H]+:  found m/z 405.3247, 
calcd 405.3264. 
 9-hexadecylamino-acridine (9n).  Yield:  35%; 1H NMR (600 MHz, 
CD3OD) δ 0.88 (t, J = 7.0 Hz, 3H), 1.22-1.34 (br, m, 22H), 1.38 (pentet, J = 7.0 
Hz, 2H), 1.47 (pentet, J = 7.6 Hz, 2H), 1.98 (pentet, J = 7.3 Hz, 2H), 4.15 (t, J = 
7.3 Hz, 2H), 7.56 (t, J = 7.6 Hz, 2H), 7.81 (d, J = 8.5 Hz, 2H), 7.96 (t, J = 7.3 Hz, 
2H), 8.495 (d, J = 8.8 Hz, 2H); HRMS (C29H43N2) [M+H]+:  found m/z 419.3407, 
calcd 419.3421. 
General Procedure for Compounds 9o-9bb:   
3-(4-Methylpiperazine-1-carbonyl)-9-propylamino-acridine) (9o).  3-(4-
Methylpiperazine-1-carbonyl)-9-phenoxy-acridine (0.25 mmol) was added to a 
round bottomed flask with 1.0 g of phenol.  Propylamine (0.5 mmol) was then 
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added and the reaction mixture was stirred at 100 °C for 1 hour.  Upon cooling, 
the reaction was diluted in CH2Cl2 and purified on silica eluting 90:10 
CH2Cl2:MeOH to 85:10:5 CH2Cl2:MeOH:Et3N.  The fractions containing the 
product were concentrated and placed under high vacuum where the product 
solidified as a yellow-orange solid.  Yield:  66%; 1H NMR (600 MHz, CD3OD) δ 
0.98 (t, J = 7.6 Hz, 3H), 1.84 (sextet, J = 7.3 Hz, 2H), 2.34 (s, 3H), 2.45 (br, s, 
2H), 2.57 (br, s, 2H), 3.56 (br, s, 2H), 3.84 (br, s, 2H), 3.88 (t, J = 7.3 Hz, 2H), 
7.32 (d, J = 8.8 Hz, 1H), 7.38 (t, J = 7.6 Hz, 1H), 7.70 (t, J = 7.6 Hz, 1H), 7.86-
7.90 (m, 2H), 8.325 (d, J = 8.8 Hz, 1H), 8.41 (d, J = 8.8 Hz, 1H); HRMS 
(C22H27N4O) [M+H]+:  found m/z 263.2190, calcd 363.2179. 
3-(4-Methylpiperazine-1-carbonyl)-9-butylamino-acridine) (9p).  Yield:  
22%; 1H NMR (600 MHz, CD3OD) δ 0.93 (t, J = 7.3 Hz, 3H), 1.43 (sextet, J = 7.3 
Hz, 2H), 1.81 (pentet, J = 7.3 Hz, 2H), 2.34 (s, 3H), 2.45 (br, s, 2H), 2.58 (br, s, 
2H), 3.56 (br, s, 2H), 3.85 (br, s, 2H), 3.93 (t, J = 7.0 Hz, 2H), 7.335 (dd, Ja = 9.1 
Hz, Jb = 1.8 Hz, 1H), 7.39 (t, J = 7.6 Hz, 1H), 7.71 (t, J = 7.9 Hz, 1H), 7.86-7.89 
(m, 2H), 8.33 (d, J = 8.5 Hz, 1H), 8.42 (d, J = 8.8 Hz, 1H); HRMS (C23H29N4O) 
[M+H]+:  found m/z 377.2344, calcd 377.2336. 
3-(4-Methylpiperazine-1-carbonyl)-9-pentylamino-acridine) (9q).  
Yield:  36%; 1H NMR (600 MHz, CD3OD) δ 0.91 (t, J = 7.0 Hz, 3H), 1.36-1.44 (m, 
4H), 1.91 (pentet, J = 7.6 Hz, 2H), 2.35 (s, 3H), 2.46 (br, s, 2H), 2.58 (br, s, 2H), 
3.53 (br, s, 2H), 3.85 (br, s, 2H), 4.03 (t, J = 7.3 Hz, 2H), 7.425 (dd, Ja = 9.1 Hz, 
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Jb = 1.8 Hz, 1H), 7.48 (m, 1H), 7.84 (m, 3H), 8.41 (d, J = 8.8 Hz, 1H), 8.495 (d, J 
= 9.1 Hz, 1H); HRMS (C24H31N4O) [M+H]+:  found m/z 391.2503, calcd 391.2492. 
3-(4-Methylpiperazine-1-carbonyl)-9-hexylamino-acridine) (9r).  Yield:  
59%; 1H NMR (600 MHz, CD3OD) δ 0.84 (t, J = 7.0 Hz, 3H), 1.26-1.30 (m, 4H), 
1.38-.142 (m, 2H), 1.83 (pentet, J = 7.3 Hz, 2H), 2.34 (s, 3H), 2.45 (br, s, 2H), 
2.58 (br, s, 2H), 3.56 (br, s, 2H), 3.85 (br, s, 2H), 3.93 (t, J = 7.0 Hz, 2H), 7.34 
(dd, Ja = 8.8 Hz, Jb = 1.5 Hz, 1H), 7.40 (t, J = 7.6 Hz, 1H), 7.73 (t, J = 7.9 Hz, 
1H), 7.86-7.89 (m, 2H), 8.335 (d, J = 8.8 Hz, 1H), 8.425 (d, J = 8.8 Hz, 1H); 
HRMS (C25H33N4O) [M+H]+:  found m/z 405.2649, calcd 405.2649. 
3-(4-Methylpiperazine-1-carbonyl)-9-heptylamino-acridine) (9s).  Yield:  
48%; 1H NMR (600 MHz, CD3OD) δ 0.85 (t, J = 7.0 Hz, 3H), 1.21-1.28 (m, 4H), 
1.29-1.37 (m, 2H), 1.37-1.43 (m, 2H), 1.86 (pentet, J = 7.3 Hz, 2H), 2.35 (s, 3H), 
2.46 (br, s, 2H), 2.58 (br, s, 2H), 3.55 (br, s, 2H), 3.85 (br, s, 2H), 3.98 (t, J = 7.3 
Hz, 2H), 7.37 (dd, Ja = 8.8 Hz, Jb = 1.5 Hz, 1H), 7.44 (t, J = 7.9 Hz, 1H), 7.77 (t, J 
= 7.6 Hz, 1H), 7.84-7.87 (m, 2H), 8.365 (d, J = 8.8 Hz, 1H), 8.45 (d, J = 9.1 Hz, 
1H); HRMS (C26H35N4O) [M+H]+:  found m/z 419.2796, calcd 419.2792. 
3-(4-Methylpiperazine-1-carbonyl)-9-octylamino-acridine) (9t).  Yield:  
37%; 1H NMR (600 MHz, CD3OD) δ 0.85 (t, J = 7.0 Hz, 3H), 1.18-1.30 (m, 8H), 
1.40 (pentet, J = 7.6 Hz, 2H), 1.84 (pentet, J = 7.3 Hz, 2H), 2.35 (s, 3H), 2.46 (br, 
s, 2H), 2.58 (br, s, 2H), 3.56 (br, s, 2H), 3.85 (br, s, 2H), 3.96 (t, J = 7.0 Hz, 2H), 
7.355 (dd, Ja = 9.1 Hz, Jb = 1.8 Hz, 1H), 7.42 (t, J = 7.6 Hz, 1H), 7.74 (t, J = 7.9 
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Hz, 1H), 7.87-7.90 (m, 2H), 8.355 (d, J = 8.5 Hz, 1H), 8.44 (d, J = 8.8 Hz, 1H); 
HRMS (C27H37N4O) [M+H]+:  found m/z 433.2965, calcd 433.2962. 
3-(4-Methylpiperazine-1-carbonyl)-9-nonylamino-acridine) (9u).  Yield:  
45%; 1H NMR (600 MHz, CD3OD) δ 0.86 (t, J = 7.0 Hz, 3H), 1.17-1.32 (m, 10H), 
1.36-1.42 (m, 2H), 1.84 (pentet, J = 7.3 Hz, 2H), 2.35 (s, 3H), 2.46 (br, s, 2H), 
2.58 (br, s, 2H), 3.56 (br, s, 2H), 3.85 (br, s, 2H), 3.95 (t, J = 7.0 Hz, 2H), 7.35 (d, 
J = 8.8 Hz, 1H), 7.41 (t, J = 7.9 Hz, 1H), 7.74 (t, J = 7.3 Hz, 1H), 7.86-7.90 (m, 
2H), 8.35 (d, J = 8.8 Hz, 1H), 8.435 (d, J = 8.8 Hz, 1H); HRMS (C28H39N4O) 
[M+H]+:  found m/z 447.3116, calcd 447.3118. 
3-(4-Methylpiperazine-1-carbonyl)-9-decylamino-acridine) (9v).  Yield:  
52%; 1H NMR (600 MHz, CD3OD) δ 0.88 (t, J = 7.0 Hz, 3H), 1.22-1.34 (m, 10H), 
1.34-1.40 (m, 2H), 1.47 (pentet, J = 7.3 Hz, 2H), 1.96 (pentet, J = 7.3 Hz, 2H), 
2.35 (s, 3H), 2.46 (br, s, 2H), 2.59 (br, s, 2H), 3.51 (br, s, 2H), 3.85 (br, s, 2H), 
4.11 (t, J = 7.3 Hz, 2H), 7.495 (dd, Ja = 8.8 Hz, Jb = 1.5 Hz, 1H), 7.55 (t, J = 7.3 
Hz, 1H), 7.79-7.83 (m, 2H), 7.93 (t, J = 7.0 Hz, 1H), 8.475 (d, J = 8.8 Hz, 1H), 
8.545 (d, J = 8.8 Hz, 1H); HRMS (C29H41N4O) [M+H]+:  found m/z 461.3268, 
calcd 461.3275. 
 3-(4-Methylpiperazine-1-carbonyl)-9-undecylamino-acridine) (9w).  
Yield:  25%; 1H NMR (600 MHz, CD3OD) δ 0.87 (t, J = 7.0 Hz, 3H), 1.18-1.32 (m, 
14H), 1.38 (pentet, J = 7.6 Hz, 2H), 1.83 (pentet, J = 7.3 Hz, 2H), 2.34 (s, 3H), 
2.45 (br, s, 2H), 2.58 (br, s, 2H), 3.56 (br, s, 2H), 3.85 (br, s, 2H), 3.93 (t, J = 7.3 
Hz, 2H), 7.34 (dd, Ja = 8.8 Hz, Jb = 1.8 Hz, 1H), 7.40 (t, J = 7.3 Hz, 1H), 7.73 (t, J 
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= 7.3 Hz, 1H), 7.87-7.89 (m, 2H), 8.335 (d, J = 8.2 Hz, 1H), 8.425 (d, J = 8.8 Hz, 
1H); HRMS (C30H43N4O) [M+H]+:  found m/z 475.3414, calcd 475.3418. 
 3-(4-Methylpiperazine-1-carbonyl)-9-dodecylamino-acridine) (9x).  
Yield:  24%; 1H NMR (600 MHz, CD3OD) δ 0.88 (t, J = 7.0 Hz, 3H), 1.20-1.36 (m, 
16H), 1.43 (pentet, J = 7.3 Hz, 2H), 1.90 (pentet, J = 7.3 Hz, 2H), 2.35 (s, 3H), 
2.46 (br, s, 2H), 2.58 (br, s, 2H), 3.53 (br, s, 2H), 3.85 (br, s, 2H), 4.02 (t, J = 7.3 
Hz, 2H), 7.42 (dd, Ja = 8.8 Hz, Jb = 1.5 Hz, 1H), 7.46-7.49 (m, 1H), 7.81-7.85 (m, 
3H), 8.40 (d, J = 8.8 Hz, 1H), 8.48 (d, J = 8.8 Hz, 1H); HRMS (C31H45N4O) 
[M+H]+:  found m/z 489.3572, calcd 489.3575. 
 3-(4-Methylpiperazine-1-carbonyl)-9-tridecylamino-acridine) (9y).  
Yield:  28%; 1H NMR (600 MHz, CD3OD) δ 0.88 (t, J = 7.0 Hz, 3H), 1.16-1.31 (m, 
18H), 1.37 (pentet, J = 7.6 Hz, 2H), 1.81 (pentet, J = 7.3 Hz, 2H), 2.34 (s, 3H), 
2.45 (br, s, 2H), 2.57 (br, s, 2H), 3.55 (br, s, 2H), 3.84 (br, s, 2H), 3.92 (t, J = 7.0 
Hz, 2H), 7.33 (dd, Ja = 8.8 Hz, Jb = 1.8 Hz, 1H), 7.39 (t, J = 7.6 Hz, 1H), 7.71 (t, J 
= 7.3 Hz, 1H), 7.86-7.89 (m, 2H), 8.325 (d, J = 8.2 Hz, 1H), 8.41 (d, J = 9.1 Hz, 
1H); HRMS (C32H47N4O) [M+H]+:  found m/z 503.3732, calcd 503.3744. 
 3-(4-Methylpiperazine-1-carbonyl)-9-tetradecylamino-acridine) (9z).  
Yield:  19%; 1H NMR (600 MHz, CD3OD) δ 0.89 (t, J = 7.0 Hz, 3H), 1.23-1.35 (m, 
18H), 1.38 (pentet, J = 7.6 Hz, 2H), 1.48 (pentet, J = 7.3 Hz, 2H), 1.98 (pentet, J 
= 7.3 Hz, 2H), 2.36 (s, 3H), 2.46 (br, s, 2H), 2.60 (br, s, 2H), 3.51 (br, s, 2H), 3.85 
(br, s, 2H), 4.14 (t, J = 7.3 Hz, 2H), 7.515 (d, J = 8.8 Hz, 1H), 7.57 (t, J = 7.9 Hz, 
1H), 7.79-7.83 (m, 2H), 7.96 (t, J= 7.6 Hz, 1H), 8.495 (d, J = 8.8 Hz, 1H), 8.565 
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(d, J = 8.8 Hz, 1H); HRMS (C33H49N4O) [M+H]+:  found m/z 517.3884, calcd 
517.3901. 
 3-(4-Methylpiperazine-1-carbonyl)-9-pentadecylamino-acridine) 
(19aa).  Yield:  23%; 1H NMR (600 MHz, CD3OD) δ 0.89 (t, J = 7.0 Hz, 3H), 1.22-
1.33 (m, 20H), 1.37 (pentet, J = 7.6 Hz, 2H), 1.46 (pentet, J = 7.6 Hz, 2H), 1.95 
(pentet, J = 7.3 Hz, 2H), 2.35 (s, 3H), 2.46 (br, s, 2H), 2.59 (br, s, 2H), 3.51 (br, s, 
2H), 3.85 (br, s, 2H), 4.10 (t, J = 7.3 Hz, 2H), 7.49 (dd, Ja = 8.8 Hz, Jb = 1.5 Hz, 
1H), 7.54 (t, J = 7.6 Hz, 1H), 7.79-7.84 (m, 2H), 7.92 (t, J = 7.0 Hz, 1H), 8.465 (d, 
J = 8.8 Hz, 1H), 8.535 (d, J = 8.8 Hz, 1H); HRMS (C34H51N4O) [M+H]+:  found 
m/z 531.4032, calcd 531.4057. 
 3-(4-Methylpiperazine-1-carbonyl)-9-hexadecylamino-acridine) (9bb).  
Yield:  26%; 1H NMR (600 MHz, CD3OD) δ 0.88 (t, J= 7.3 Hz, 3H), 1.19-1.35 (m, 
24H), 1.41 (pentet, J = 7.3 Hz, 2H), 1.87 (pentet, J = 7.3 Hz, 2H), 2.34 (s, 3H), 
2.45 (br, s, 2H), 2.58 (br, s, 2H), 3.53 (br, s, 2H), 3.84 (br, s, 2H), 3.99 (t, J = 7.3 
Hz, 2H), 7.395 (dd, Ja = 8.8 Hz, Jb = 1.2 Hz, 1H), 7.45 (t, J = 7.0 Hz, 1H), 7.77-
7.84 (m, 3H), 8.37 (d, J = 8.8 Hz, 1H), 8.455 (d, J = 8.8 Hz, 1H); HRMS 
(C35H53N4O) [M+H]+:  found m/z 545.4216, calcd 545.4214. 
9-oxo-9,10-dihydroacridine-3-carboxyilic acid (10):  2-
phenylaminoterephthalic acid (15.55 mmol) was dissolved in excess 
polyphosphoric acid and stirred at 145° C for 3 hours.  Upon cooling, the mixture 
was dumped into 600mL of water and a solid precipitated, which was collected 
via filtration and washed with water.  The resultant solid was taken into 1:1 5% 
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NaOH:MeOH (60 mL) and filtered. The filtrate was taken to pH 5.0 with acetic 
acid and allowed to precipitate overnight.  The precipitate was collected via 
filtration and washed with water to yield 2.3g of yellow solid (9.62 mmol).  Yield:  
62%.  1H NMR (400 MHz, DMSO-d6) δ 7.28 (t, J= 7.6 Hz, 1H), 7.57 (d, J= 8.4 Hz, 
1H), 7.75 (m, 2H), 8.19 (s, 1H), 8.24 (dd, Ja= 8.1 Hz, Jb= 1.1 Hz, 1H), 8.28 (d, J= 
8.4 Hz, 1H), 12.01 (s, 1H); HRMS (C14H8NO3) [M-H]-:  found m/z 238.0519, calcd 
238.0510. 
General Procedure for Compounds 11a-11n:   
 N-propyl-9-oxo-9,10-dihydroacridine-3-carboxamide (11a):  9-oxo-
9,10-dihydroacridine-3-carboxyilic acid (1 mmol), propylamine (1.2 mmol), BOP-
Cl (1.2 mmol), and Et3N (3 mmol) were dissolved in 20mL dry DMF and stirred at 
room temperature overnight.  The reaction mixture was added to 100mL of 5% 
NaHCO3 and stirred for 1 hour.  A solid precipitated and was collected via 
filtration, washed with water, and recrystallized from MeOH/H2O to afford 50 mg 
of yellow/orange solid (0.18 mmol).  Yield:  18%; 1H NMR (400 MHz, DMSO-d6) δ 
0.93 (t, J= 7.4 Hz, 3H), 1.58 (m, 2H), 3.27 (m, 2H), 7.28 (t, J= 7.4 Hz, 1H), 7.56 
(d, J= 8.6 Hz, 1H), 7.64 (d, J= 7.6 Hz, 1H), 7.76 (t, J= 7.1 Hz, 1H), 7.99 (s, 1H), 
8.24 (d, J= 7.8 Hz, 1H), 8.27 (d, J= 8.4 Hz, 1H), 8.71 (t, J= 5.2 Hz, 1H), 11.89 (s, 
1H); HRMS (C17H17N2O2) [M+H]+:  found m/z 281.1294, calcd 281.1285. 
 N-butyl-9-oxo-9,10-dihydroacridine-3-carboxamide (11b):  Yield:  
24%; 1H NMR (400 MHz, DMSO-d6) δ 0.99 (t, J= 7.24, 3H), 1.37 (sextet, J= 7.24, 
2H), 1.55 (pentet, J= 7.24, 2H), 3.29 (m, 2H), 7.26 (t, J= 7.5, 1H), 7.56 (d, J= 
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7.56, 1H), 7.63 (d, J=  8.41, 1H), 7.76 (m, 1H), 7.98 (s, 1H), 8.25 (dd, J= 8.41, 
13.50, 2H), 8.70 (m, 1H), 11.89 (s, 1H); HRMS (C18H19N2O2) [M+H]+:  found m/z 
295.1444, calcd 295.1441. 
 N-pentyl-9-oxo-9,10-dihydroacridine-3-carboxamide (11c):  Yield:  
23%; 1H NMR (400 MHz, DMSO-d6) δ 0.90 (m, 3H), 1.33 (m, 4H), 1.56 (m, 2H), 
3.28 (m, 2H), 7.25 (t, J= 7.4 Hz, 1H), 7.54 (d, J= 8.4 HZ, 1H), 7.56 (d, J= 8.6 Hz, 
1H), 7.72 (m, 1H), 7.99 (s, 1H), 8.20 (d, J= 7.8 Hz, 1H), 8.23 (d, J= 8.2 Hz, 1H), 
8.67 (m, 1H), 11.90 (s, 1H); HRMS (C19H21N2O2) [M+H]+:  found m/z 309.1586, 
calcd 309.1598. 
 N-hexyl-9-oxo-9,10-dihydroacridine-3-carboxamide (11d):  Yield:  
9%; 1H NMR (400 MHz, DMSO-d6) δ 0.99 (t, J= 6.65 Hz, 3H), 1.25-1.40 (m, 6H), 
1.55 (m, 2H), 3.29 (m, 2H), 7.26 (t, J= 7.5 Hz, 1H), 7.56 (d, J= 8.02 Hz, 1H), 7.63 
(dd, J= 1.37 Hz, 8.41 Hz, 1H), 7.76 (m, 1H), 7.98 (s, 1H), 8.25 (dd, J= 8.41 Hz, 
13.50 Hz, 2H), 8.70 (m, 1H), 11.89 (s, 1H); HRMS (C20H23N2O2) [M+H]+:  found 
m/z 323.1757, calcd 323.1754. 
 N-heptyl-9-oxo-9,10-dihydroacridine-3-carboxamide (11e):  Yield:  
39%; 1H NMR (400 MHz, DMSO-d6) δ 0.99 (m, 3H), 1.25-1.40 (m, 8H), 1.55 (m, 
2H), 3.29 (q, J= 6.26 Hz, 2H), 7.26 (t, J= 7.5 Hz, 1H), 7.56 (d, J= 8.02 Hz, 1H), 
7.63 (dd, J= 1.37 Hz, 8.41 Hz, 1H), 7.76 (m, 1H), 7.98 (s, 1H), 8.25 (dd, J= 8.41 
Hz, 13.50 Hz, 2H), 8.70 (m, 1H), 11.89 (s, 1H); HRMS (C21H25N2O2) [M+H]+:  
found m/z 337.1911, calcd 337.1911. 
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 N-octyl-9-oxo-9,10-dihydroacridine-3-carboxamide (11f):  Yield:  
45%; 1H NMR (400 MHz, DMSO-d6) δ 0.86 (m, 3H), 1.25-1.40 (m, 10H), 1.55 (m, 
2H), 3.30 (m, 2H), 7.26 (t, J= 7.5 Hz, 1H), 7.56 (d, J= 8.02 Hz, 1H), 7.63 (dd, J= 
1.37 Hz, 8.41 Hz, 1H), 7.76 (m, 1H), 7.98 (s, 1H), 8.25 (dd, J= 8.41 Hz, 13.50 Hz, 
2H), 8.70 (m, 1H), 11.89 (s, 1H); HRMS (C22H27N2O2) [M+H]+:  found m/z 
351.2069, calcd 351.2067. 
 N-nonyl-9-oxo-9,10-dihydroacridine-3-carboxamide (11g):  Yield:  
40%; 1H NMR (400 MHz, DMSO-d6) δ 0.86 (m, 3H), 1.25-1.40 (m, 12H), 1.55 (m, 
2H), 3.30 (q, J= 6.26 Hz, 2H), 7.26 (t, J= 7.5 Hz, 1H), 7.56 (d, J= 8.02 Hz, 1H), 
7.63 (dd, J= 1.17 Hz, 8.41 Hz, 1H), 7.76 (m, 1H), 7.98 (s, 1H), 8.25 (dd, J= 8.41 
Hz, 13.50 Hz, 2H), 8.70 (m, 1H), 11.89 (s, 1H); HRMS (C23H29N2O2) [M+H]+:  
found m/z 365.2226, calcd 365.2224. 
 N-decyl-9-oxo-9,10-dihydroacridine-3-carboxamide (11h):  Yield:  
32%; 1H NMR (400 MHz, DMSO-d6) δ 0.84 (t, J= 6.3 Hz, 3H), 1.16-1.39 (m, 
14H), 1.55 (m, 2H), 3.28 (m, 2H), 7.28 (t, J= 7.4 Hz, 1H), 7.56 (d, J= 8.2 Hz, 1H), 
7.63 (d, J= 8.2 Hz, 1H), 7.75 (t, J= 7.2 Hz, 1H), 7.99 (s, 1H), 8.24 (d, J= 8.2 Hz, 
1H), 8.27 (d, J= 8.2 Hz, 1H), 8.69 (t, J= 5.5 Hz, 1H), 11.89 (s, 1H); HRMS 
(C24H31N2O2) [M+H]+:  found m/z 379.2380, calcd 379.2380. 
 N-undecyl-9-oxo-9,10-dihydroacridine-3-carboxamide (11i):  Yield:  
18%; 1H NMR (400 MHz, DMSO-d6) δ 0.84 (m, 3H), 1.17-1.37 (m, 16H), 1.55 (m, 
2H), 3.28 (m, 2H), 7.27 (t, J= 7.4 Hz, 1H), 7.56 (d, J= 8.6 Hz, 1H), 7.62 (dd, Ja= 
8.3 Hz, Jb= 1.3 Hz, 1H), 7.75 (t, J= 7.0 Hz, 1H), 7.99 (s, 1H), 8.22 (m, 1H), 8.26 
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(d, J= 8.4 Hz, 1H), 8.69 (t, J= 5.4 Hz, 1H), 11.92 (s, 1H); HRMS (C25H33N2O2) 
[M+H]+:  found m/z 393.2523, calcd 393.2537. 
 N-dodecyl-9-oxo-9,10-dihydroacridine-3-carboxamide (11j):  Yield:  
18%; 1H NMR (400 MHz, DMSO-d6) δ 0.83 (t, J= 6.7 Hz, 3H), 1.14-1.42 (m, 
18H), 1.55 (m, 2H), 3.28 (m, 2H), 7.27 (t, J= 7.5 Hz, 1H), 7.56 (d, J= 8.2 Hz, 1H), 
7.62 (dd, Ja= 8.4 Hz, Jb= 1.4 Hz, 1H), 7.74 (m, 1H),  7.99 (s, 1H), 8.23 (dd, Ja= 
8.1 Hz, Jb= 1.3 Hz, 1H), 8.26 (d, J= 8.4 Hz, 1H), 8.69 (t, J= 5.5 Hz, 1H), 11.91 (s, 
1H); HRMS (C26H35N2O2) [M+H]+:  found m/z 407.2706, calcd 407.2693. 
 N-tridecyl-9-oxo-9,10-dihydroacridine-3-carboxamide (11k):  Yield:  
28%; 1H NMR (400 MHz, DMSO-d6) δ 0.83 (t, J= 6.8 Hz, 3H), 1.14-1.42 (m, 
20H), 1.55 (m, 2H), 3.28 (m, 2H), 7.27 (t, J= 7.4 Hz, 1H), 7.56 (d, J= 8.4 Hz, 1H), 
7.62 (dd, Ja= 8.5 Hz, Jb= 1.3 Hz, 1H), 7.75 (m, 1H),  7.99 (s, 1H), 8.23 (m, 1H), ), 
8.26 (d, J= 8.4 Hz, 1H), 8.69 (t, J= 5.4 Hz, 1H), 11.91 (s, 1H); HRMS 
(C27H37N2O2) [M+H]+:  found m/z 421.2830, calcd 421.2823. 
 N-tetradecyl-9-oxo-9,10-dihydroacridine-3-carboxamide (11l):  
Yield:  38%; 1H NMR (400 MHz, DMSO-d6) δ 0.83 (t, J= 6.7 Hz, 3H), 1.14-1.42 
(m, 22H), 1.55 (m, 2H), 3.28 (m, 2H), 7.27 (m, 1H), 7.56 (d, J= 8.2 Hz, 1H), 7.6 
(d, J= 8.8 Hz, 1H), 7.77 (m, 1H), 7.99 (s, 1H), 8.23 (d, J= 8.6 Hz, 1H), 8.26 (d, J= 
8.2 Hz, 1H), 8.72 (m, 1H), 11.88 (s, 1H); HRMS (C28H39N2O2) [M+H]+:  found m/z 
435.3014, calcd 435.3013. 
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 N-pentadecyl-9-oxo-9,10-dihydroacridine-3-carboxamide (11m):  
Yield:  42%; 1H NMR (400 MHz, DMSO-d6) δ 0.84 (t, J= 6.7 Hz, 3H), 1.14-1.42 
(m, 24H), 1.55 (m, 2H), 3.28 (m, 2H), 7.26 (m, 1H), 7.55 (d, J= 8.8 Hz, 1H), 7.60 
(d, J= 9.0 Hz, 1H), 7.73, (m, 1H), 7.99 (s, 1H), 8.23 (d, J= 8.0 Hz, 1H), 8.26 (d, J= 
8.6 Hz, 1H), 8.67 (m, 1H), 11.92 (s, 1H); HRMS (C29H41N2O2) [M+H]+:  found m/z 
449.3183, calcd 449.3163 
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Chapter 4:  Synthesis and Evaluation of Acridine and Acridone Epoxides 
with Anti-bacterial Activity 
Introduction 
Acridone alkaloids are a diverse class of natural products.  The main source of 
the acridone alkaloids is the Rutaceae family of plants.116,117  Acridones have 
been tested in vitro and found to be active against cancers,118 herpes,119 
psoriasis,120 and malaria,121  Despite their broad activity, there has been very 
little work looking at acridone based compounds as anti-bacterial agents.  One 
recent study looked at a small sample of N-alkylated acridone products against 
both gram positive and negative bacteria.  It was found that these simple 
acridones possess moderate anti-bacterial activity when compared to 
ciprofloxacin.122  Another recent study looked at the effects of coupling 
oxadiazoles to the basic acridone core and found them to posses moderate 
activity against a small sampling of gram positive and negative bacteria.123  
Outside of these two recent studies, there has not been much reported on the 
development of acridone based anti-bacterial agents. 
With the ever changing landscape of bacterial drug resistance, a pressing need 
exists for the development of new drugs with either improved activity against 
known targets or drugs with novel mechanisms of action.  One of the most 
prevalent of these drug resistant bacteria is Methicillin-resistant Staphylococcus 
aureus (MRSA).  Known since the 1960's,89 MRSA has evolved from being 
mainly isolated to health care settings to being prevalent throughout the 
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community.87  In the United States, community associated MRSA is 
predominantly caused by two strains, USA300 and USA400.91  Of these two 
strains, the USA300 strain is the most prevalent and it contains genes for 
Panton-Valentine leukocidin (PVL) which is a known virulence factor associated 
with MRSA infections and complications associated with the infection such as 
bacteremia.124  While the USA300 strain has taken over as the most prominent 
strain in the United States, the USA400 strain is still prevalent and contains many 
of the same virulence factors that the USA300 strain has along with several of 
the same clinical indications such as necrotizing pneumonia.125 
Herein we report the synthesis of acridine, acridone, and xanthone compounds 
bearing 1,2-epoxypropyl substituents at varying positions that show promising 
activity against both USA300 and USA400 strains of MRSA.  Ring opened 1,2-
diol analogues were also synthesized as controls to probe the necessity of the 
epoxide.  All compounds that were active against at least one strain of MRSA 
were subjected to a vero cell cytotoxicity assay as a measure of general toxicity 
of the compounds.  To probe the mechanism of action, a select sampling of 
active compounds were screened in a whole cell assay in an attempt elucidate 
mechanism of action. 
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Synthesis 
 
 
 
 
 
 
 
 
 
 
 
 
Shown in Scheme 3, synthesis of the acridone based compounds started with a  
condensation between phloroglucinol 1 and methyl anthranilate 2 to give the 1,3-
dihydroxy acridone 4.  Treatment of acridone 4 with cesium carbonate followed 
by epibromohydrin afforded the desired epoxy acridones 6-8.  By only using a 
slight excess of epibromohydrin, we were able to isolate both analogs 6 and 7 
from one reaction.  When we used a large excess of epibromohydrin, we were 
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Scheme 3:  Synthesis of Acridone and Xanthone Epoxides.  Reagents and 
conditions:  (a) PTSA, Hexanol, reflux; (b) POCl3, Zn, 70 °C; (c) 
Epibromohydrin, Cs2CO3, Acetone/DMF, 40-70 °C; (d) 20% NaOH (aq), 70 °C 
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able to drive the reaction to alkylate all three positions and isolate 8 as the major 
product.  Hydrolysis of the acridone epoxides 6 and 7 to the respective diols 11-
12 was accomplished in good yields by stirring overnight in 20% aqueous sodium 
hydroxide. 
In the case of the xanthone analogs, phloroglucinol 1 was condensed with 
salicylic acid 3 in phosphorous oxychloride with zinc to afford the 1,3-dihydroxy 
xanthone 5.  Using the same system as for the acridones in which only a slight 
excess of epibromohydrin was used, both the mono and di-epoxy xanthones 9-
10 were synthesized in one pot. 
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Scheme 4:  Synthesis of acridine analogs.  Reagents and conditions:  (a) i. 
Pd(OAc)2, dppf, Cs2CO3, toluene, 95 °C, ii. 5% NaOH, acetone, rt; (b) POCl3, 
125 °C; (c) Phenol, 80 °C; (d) BBr3, DCM, rt; (e) amine, phenol, 100 °C; (f) 
Epibromohydrin, Cs2CO3, DMF/MeCN, 70 °C; (g) 3-chloro-1,2-propanediol, 
Cs2CO3, DMF/MeCN, 70 °C 
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Shown in Scheme 4, synthesis of the acridine analogs began with a modified 
Buchwald-Hartwig amination reaction7 between methyl-2-iodobenzoate 14 and 
the appropriate anisidine 13.  We chose to use the Buchwald-Hartwig amination 
reaction here due to the poor yields and messy reactions given by the traditional 
Ullmann-Jourdan reaction, especially on our substrates which lack strong 
electron-withdrawing groups.   Hydrolysis of the methyl ester affords carboxylic 
acids 15a and 15b.  The choice to use anisidines was due to the instability of 
phenols towards phosphorous oxychloride which is used to cyclize 15a and 15b 
to the 9-chloroacridines 16 and 17.  9-chloroacridines 16 and 17 were reacted 
with molten phenol to give stable 9-phenoxy intermediates 19a and 19b.  At this 
stage of the synthesis it was decided, to de-protect the protected phenols to 
allow for more rapid diversification of the scaffold.   
Due to the 9 position of a substituted acridine being amenable to either 
nucleophilic aromatic substitution or hydrolysis, we attempted to find mild 
conditions that would cleave the methyl ester to the phenol.  Our first attempt at 
demethylation was to try an aluminum chloride and 1-dodecanethiol system.126  
In our hands, this reaction failed to give any desired hydroxy acridine compound 
but instead gave a complex mixture of side products.  We then tried a sodium 
methoxide and 1-dodecanethiol system which was reported to be mild and 
selective for aromatic methyl ethers,127 however on our system, this reaction 
failed to afford our desired hydroxy acridine as well and only returned mostly 
starting material with some minor side products.  We ultimately settled on using 
boron tribromide in dichloromethane at room temperature128 to afford the  desired 
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hydroxy acridine intermediates 20 and 21 in moderate yields due to the likely 
hydrolysis or decomposition of the 9-phenoxyacridine in the presence of small 
amounts of HBr.  
 With hydroxy acridines 20 and 21 in hand, treatment of 20 with each respective 
primary amine in phenol at 100 °C afforded the desired 9-amino-hydroxy 
acridines 22a-c in moderate to good yields.  Alkylation of each derivative of 22 
with epibromohydrin in dimethylformamide/acetonitrile (1:1) using cesium 
carbonate as a base gave us our desired 9-amino acridine epoxides 23-25. In the 
case of the 9-amino-4-hydroxy acridines derived from 21 following the same 
method used for 22, we were unsuccessful in obtaining pure 9-amino-4-epoxy 
acridines.  Despite utilizing many different column conditions and both silica and 
basic alumina, we were never able to separate the unidentified impurity that was 
co-eluting with our desired compounds. 
Our decision to use the N-methylated tryptamine stemmed from our inability to 
selectively alkylate the phenol on the acridine in the presence of the free indole 
NH.  This is likely due to the similar pKa values of the indole nitrogen (~21)129 to 
the phenol (~18)130 in dimethylsulfoxide (we expect pKa values to be similar in 
our dimethylformamide solvent system).  To accomplish this, we followed a 
previously published procedure.131  Using this as the amine instead of tryptamine 
gave us easy access to our desired analogs in which the epoxide is linked 
through the phenol on the acridine ring. 
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Our attempts to use a similar hydrolysis of the epoxide as we did with the 
acridones failed to yield our desired 1,2-diols.  This is due to the sensitivity of 9-
amino acridines to hydrolysis to the acridone under basic, aqueous conditions.132  
This meant we had to introduce the diol directly.  To allow for a more expedient 
synthesis of analogs, instead of waiting until the final stage to alkylate the 
hydroxy acridines 20 and 21, we used the same 
dimethylformamide/acetonitrile/cesium carbonate system to alkylate the 9-
phenoxy-hydroxy acridine using 3-chloro-1,2-propanediol to afford the 9-phenoxy 
acridine diols 26 and 27.  Using the same conditions described above for 
introducing the 9-amino group afforded the desired 9-amino acridine diol 
compounds 28-33.  Unlike the case of the 4-substituted acridine epoxides, since 
we alkylated the 4-position prior to installing the amine, we did not have the same 
purification issue we had with the epoxides, which allowed us to access all of our 
desired diol analogs. 
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Results and Discussion 
 
 
 
 
 
 
 
 
 
 
Shown in Table 2 are the results for the acridone and xanthone based 
compounds.  In the case of compounds 4 and 5 in which there was no 
substitution off either the acridone or xanthone ring, the compounds showed no 
anti-bacterial activity.  When an epoxy group was substituted at the 3- position 
only, acridone 6 showed slight anti-bacterial activity while xanthone 9 still showed 
no activity.  When substituted at both the 1- and 3- position, acridone 7 and 
xanthone 10 both showed significant anti-bacterial activity against both strains of 
MRSA and MSSA.  Given the increase in activity with the increase in substitution, 
        MIC:  (µM)   
Cpd X R1 R2 USA400 (MW2) 
USA300 
(1371) 
MSSA 
(MSA553) 
Vero 
Cell 
Toxicity 
4 NH OH OH >100 >100 >100 NT 
5 O OH OH >100 >100 >100 NT 
6 NH Epoxya OH >100 >100 >100 >100 
7 NH Epoxy Epoxy 23.6 47.1 23.6 94.3 
8 N-Epoxy Epoxy Epoxy 80.9 40.5 20.2 >100 
9 O Epoxy OH >100 >100 >100 >100 
10 O Epoxy Epoxy 23.5 23.5 11.8 94.0 
11 NH Diolb OH >100 >100 >100 NT 
12 NH Diol Diol >100 >100 >100 NT 
 
Table 2:  Anti-bacterial Data and Vero Cell (kidney epithelial cells) 
Toxicity (µM).  aEpoxy denotes 1,2-epoxypropane, bDiol denotes 1,2-
propanediol, NT = not tested 
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we were surprised when the addition of a third epoxy group in compound 8 
actually showed a decrease in activity.  These compounds also showed 
moderate toxicity towards vero cells, however there is a 2-4 fold difference 
between anti-bacterial activity and vero cell toxicity indicating a possibility for a 
narrow therapeutic window.  When we ring opened the two most active acridones 
to their respective diols, all anti-bacterial activity was lost which is strong 
evidence that these compounds are exerting their activity via the epoxide, likely 
through a mechanism that involves either DNA or protein alkylation.  In an 
attempt to elucidate what this possible site of alkylation may be, these 
compounds were tested in an assay in which a small library of antisense RNA 
was used to down regulate selected tRNA synthetases, the subunits A and B of 
DNA gyrase, and bacterial topoisomerase IV.  Down regulation of these 
synthetases and enzymes produces strains that are hyper-sensitive to anti-
bacterial agents if the compound is acting via the down regulated target.133,134  In 
this assay, our most active compounds failed to show an increase in activity in 
the sensitized strains which suggests these compounds are not acting via a 
specific target we tested for.  
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Shown in Table 3 is our data on the anti-bacterial activity and vero cell toxicity of 
the acridine based compounds bearing either epoxy or diol substituents.  Unlike 
the acridone and xanthone based compounds, compounds 22a-22f, lacking 
either an epoxy or diol substituent showed good to excellent anti-bacterial 
activity.  It is interesting to note that within the acridines, compounds 22a, 22d, 
23, 28, and 31 bearing an octylamino group at the 9-position showed the highest 
MIC:  (µM) 
Cpd R1 R2 R3d USA400 (MW2) 
USA300 
(1371) 
MSSA 
(MSA553) 
Vero 
Cell 
Toxicity
22a H OH 8C 6.2 3.1 3.1 49.6 
22b H OH 4A1BP 83.4 41.7 83.4 >100 
22c H OH NMeTryp >100 21.8 21.8 87.1 
22d OH H 8C 49.6 24.8 24.8 99.2 
22e OH H 4A1BP 83.4 41.7 41.7 >100 
22f OH H NMeTryp 43.5 43.5 43.5 >100 
23 H Epoxy 8C 10.6 21.1 5.3 42.3 
24 H Epoxy NMeTryp 75.6 18.9 18.9 75.6 
25 H Epoxy 4A1BP 18.2 18.2 9.1 72.8 
28 H Diol 8C 80.7 10.1 10.1 40.4 
29 H Diol NMeTryp >100 >100 >100 >100 
30 H Diol 4A1BP >100 >100 >100 NT 
31 Diol H 8C 10.1 10.1 10.1 40.4 
32 Diol H 4A1BP >100 72.5 72.5 >100 
33 Diol H NMeTryp >100 69.9 69.9 >100 
 
Table 3:  Anti-Bacterial Activity and Vero Cell Toxicity of Acridine Based 
Compounds (µM).  aEpoxy denotes 1,2-epoxypropane, bDiol denotes 1,2-
propanediol, NT = not tested, d8C = octylamino, 4A1BP = 4-amino-1-
benzyliperidinyl, NMeTryp = 1-methyl-tryptamino 
 
59 
 
activity regardless of ring substitution.  The vero cell toxicity followed this same 
trend, which is indicative of these compounds acting through a target that is not 
specific to bacteria.  When comparing the ring opened diols 29 and 30 to their 
epoxide counterparts 24 and 25, there was a significant drop in anti-bacterial 
activity which mirrors what we saw in the acridone and xanthone series.  This 
however was not the case in the 9-octylamino compounds 23 and 28, which 
showed no significant drop off between the epoxy and diol analogs which 
suggests these particular analogs are unique in the way they are killing the 
bacteria. 
We believe this is due to the unique nature of long chain 9-alkylamino groups on 
acridines.   In another study which looked at the effect of differing length of 9-
alkylamino substituent's on acridines, we found that the longer the tail length, the 
higher the anti-bacterial activity up until the alkylamino group reaches between 9 
and 12 carbons, depending on the other substitutions on the acridine (see 
previous chapter).  While the normally accepted mechanism of action of the 
acridines, both against cancer and bacteria is the DNA via its ability to 
intercalate, we found that the most potent anti-bacterial compounds were also 
the worst intercalators, which suggests the anti-bacterial activity is driven by the 
9-alkylamino group.  This appears to be the case as well for compounds 23 and 
28 as they did not show a significant drop in activity between the epoxide and 
diol like the other analogs did.  In the case of these analogs, it does not appear 
that the addition of an epoxide group has any effect on the activity of the 
compounds as it does in the other acridine, acridone, and xanthone analogs. 
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Conclusions 
We have presented here the anti-bacterial activity and vero cell toxicity of 
acridine, acridone, and xanthone based compounds bearing either 1,2-
epoxypropane or 1,2-propanediol substituents.  When examining the acridone 
and xanthone compounds which are generally not believed to be compounds that 
intercalate DNA,103 the addition of two epoxy groups at the 1- and 3- position 
exhibited good anti-bacterial activity with moderate toxicity.  In an attempt to 
elucidate the mechanism of action of these compounds, they were tested in an 
antisense RNA sensitization assay against a small library of tRNA synthetases 
along with the A and B subunits of DNA gyrase and bacterial topoisomerase IV.  
In this set of assays, none of the tRNA or enzymes tested for were determined to 
be the target for the acridone and xanthone epoxides.  Given that compound 7 
bearing an epoxy group at both the 1- and 3- position showed the highest activity 
along with a fourfold increase in activity for bacteria over vero cells suggests that 
while the target for these compounds is unknown, there is something special 
about the di-epoxy acridone that could make it a useful anti-bacterial agent.  
More work is warranted to determine the mechanism of action of this particular 
analog. 
In the case of our acridine-based compounds, almost every compound showed 
some degree of activity.  This is likely due to the established target of the DNA 
and its related enzymes for most acridine based compounds, which makes them 
less dependent on their substitution to drive their activity.  Interestingly in the 
case of the 4-amino-1-benzyl-piperidine and 1-methyl-tryptamino analogs, the 
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addition of the epoxide moiety in the 4 position did not showed a marked 
improvement in anti-bacterial activity or toxicity compared to the un-substituted 
phenolic acridine, however the ring opening of this epoxide to the 1,2-diol caused 
a marked loss in activity against the strains of S. aureus.  Future work to 
elucidate the mechanism of action of these compounds would be to test them in 
the anti-sense RNA assay and test the degree of their DNA intercalation to see if 
they are hitting a different target or if somehow the 1,2-diol group interferes with 
the ability of the acridine to intercalate into the DNA helix. 
In the special case of the 9-octylamino acridines, regardless of the substitution or 
lack thereof, these compounds maintained excellent activity against S. aureus 
along with an increased toxicity compared to the other acridine compounds.  We 
believe this is due to the special nature of how these long chain 9-alkylamino 
acridines interact with the cells.  Our previous unpublished work suggests that 
these long chain 9-alkylamino compounds do not intercalate DNA but rather act 
on some other cellular target.  Looking at similar compounds and the literature, 
we have postulated that these compounds act as cell membrane disruptors due 
to the cationic acridine "head" and greasy aliphatic tail acting as an amphiphile of 
sorts in which the tail inserts into the membrane and the positively charged 
acridine "head" interacts with the high density of negative charges associated 
with the bacterial cell membrane.109  We believe this is the case in these 
compounds as well as our other series due to the fact that unlike the other 
compounds we have presented in this paper, there is no difference in activity 
between the phenolic, epoxy, and diol 9-octylamino compounds.  Further studies 
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would be warranted to carry out a cell membrane disruption assay to test this 
theory and more SAR work needs to be done in an attempt to retain potency 
while cutting down on the toxicity of these compounds to possibly develop a 
novel anti-bacterial agent to combat the ever growing threat of drug-resistant 
bacteria. 
Experimental 
Biology General 
S. aureus strains used in this study include MRSA isolates MW2 (USA400) and 
1371 (USA300) and MSSA isolate MSA553.  The S. aureus cells were cultured in 
Trypticase soy broth (TSB) at 37˚C with shaking.   
S. aureus susceptibility assay   
S. aureus strains were grown in TSB at 37C overnight and were diluted to ~105 
CFU/ml as cultures for MIC assays with a 96-well microtiter format.  Serial 
dilutions of 40 standard compounds were prepared in TSB-Erm in a final assay 
volume of 100 l.   Fifty l of 105 CFU/ml bacteria was added to the serially 
diluted antibiotics.  The MIC was considered to be the concentration at which the 
antibiotic prevented turbidity in the well after incubation for18 h at 37C.  The MIC 
assay was repeated three times, and the table in the results section represented 
one experiment. 
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Cell culture 
Vero monkey kidney epithelial cells (ATCC CCL-81) were cultured in RPMI 
1640 medium supplemented with 10% fetal bovine serum (FBS; Invitrogen, CA).  
Cultures of Vero cells were maintained in a medium containing penicillin (5µg/ml) 
and streptomycin (100µg/ml) (Invitrogen, CA).  Assays were performed in RPMI 
1640 medium with different doses of tested compounds. 
Cytotoxicity assays   
The cytotoxicity assay was conducted by measuring LDH release as 
described135.  Briefly, all cells were grown in 96-well plates to 90% confluence. 
To test the cytotoxicity, monolayer cells were exposed to different doses of tested 
compounds and incubated for 16 h at 37ºC with 5% CO2.  At the end of the 
experiment, cell viability was determined by measuring LDH release using the 
CellTiter 96® Aqueous Non-Radioactive Cell Proliferation Assay (Promega, MI) 
as per manufacturer’s instructions.  Each experiment was repeated three times, 
and all of the percentage of cell death related to control (no death) were 
calculated.  
Chemistry General 
1,3-dihydroxyacridin-9(10H)-one (4):  A mixture of methyl anthranilate (6.6 
mmol), phloroglucinol (6.6 mmol), and p-toluene-sulfonic acid (100 mg) in 40 mL 
of hexanol was heated at reflux for 4 h. The reaction mixture was then cooled, 
petroleum ether was added, and the mixture stirred well. The product was then 
filtered and washed with petroleum ether followed by dichloromethane.  The 
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resultant solid was recrystallized from ethanol/water to yield 1.28 g (5.63 mmol) 
of a yellow solid.  85% yield.  1H-NMR (DMSO-d6): 5.97 (d, J = 1.2 Hz, 1H), 6.26 
(d, J = 0.6 Hz, 1H), 7.22 (t, J = 7.5 Hz, 1H), 7.43 (d, J = 9.0 Hz, 1H), 7.68 (t, J = 
7.8, 7.2  Hz, 1H), 8.12 (d, J = 8.4 Hz, 1H), 10.49 ( s, 1H), 11.72 ( s, 1H), 14.72 (s, 
1H). 
General procedure for mono and di-epoxy-acridones:  1,3-dihydroxyacridin-
9(10H)-one (1.1 mmol) and Cs2CO3 (2.2 mmol) was dissolved in 40 mL of a 1:2 
DMF:Acetone mixture.  Epibromohydrin (1.23 mmol) was added and the reaction 
was heated at 40 °C for 16 hours.  The reaction was cooled and diluted with 
water, then extracted with ethyl acetate.   The combined organics were washed 
with brine, dried over Na2SO4 and concentrated in vacuo.  The residue was 
purified on silica eluting 2:1 Hex:EtOAc to afford both the mono-epoxy and di-
epoxy acridone as yellow solids. 
1-hydroxy-3-(oxiran-2-ylmethoxy)acridin-9(10H)-one  (6) 
52% yield.  1H-NMR (600 MHz, DMSO-d6):  δ 2.74 (m, 1H), 2.86 (t, J = 4.8 Hz, 
1H), 3.35 (m, 1H), 3.92 (m, 1H), 4.42-4.45 (dd, J = 2.4, 9.0 Hz, 1H), 6.18 (d, J = 
2.4 Hz, 1H), 6.37 (s, 1H), 7.26 (t, J = 7.7 Hz, 1H), 8.15 (d, J = 8.1 Hz, 1H), 11.9 
(s, 1H),  14.22 (s, 1H); HRMS (C16H13NO4) [M-H]-:  found m/z 282.0741, calcd 
282.0772 
1,3-bis(oxiran-2-ylmethoxy)acridin-9(10H)-one (7) 
22% yield.  1H-NMR (600 MHz, DMSO-d6):  δ 2.63 (m, 1H), 2.74 (m, 1H), 2.82 
(m, 1H), 2.87 (m, 1H), 3.37 (m, 1H), 3.45 (m, 1H), 3.98 (m, 1H), 4.44-4.52 (m, 
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2H), 4.97 (dd, 1H) 6.33 (d, J = 2.4 Hz 1H), 6.67 (t, J = 1.8 Hz, 1H), 7.35 (t, J = 6.6 
Hz, 1H), 7.82 (m, 2H), 8.28 (d, J = 6.6 Hz, 1H); HRMS (C19H17 NO5) [M+H]+:  
found m/z 340.1184, calcd 340.1179. 
1,3-bis(oxiran-2-ylmethoxy)-10-(oxiran-2-ylmethyl)acridin-9(10H)-one (8) 
1,3-dihydroxyacridin-9(10H)-one (2.2 mmol) and Cs2CO3 (11 mmol) was 
dissolved in 20 mL of DMF.  Epibromohydrin (22 mmol) was added and the 
reaction was heated at 70 °C for 16 hours.  The reaction was cooled and diluted 
with water, then extracted with ethyl acetate.  The combined organics were 
washed with brine, dried over Na2SO4 and concentrated in vacuo.  The residue 
was purified on silica eluting 2:1 Hex:EtOAc to yield a yellow solid.  26% yield.  
1H-NMR (600 MHz, DMSO-d6):  δ 2.65 (m, 1H), 2.74 (m, 1H), 2.84-2.89 (m, 3H), 
3.08 (m, 1H), 3.39 (m, 2H), 3.46 (m, 1H), 4.02 (m, 2H), 4.37 (m, 2H), 4.51 (d, J = 
11.4 Hz, 1H), 4.88-4.91 (dd, J = 4.8, 12.0 Hz, 1H), 6.45 (s, 1H), 6.76 (s, 1H), 7.24 
(t, J = 7.8 Hz, 1H), 7.68 (m, 2H), 8.20 (d, J = 7.2 Hz, 1H); HRMS (C22H21 NO6) 
[M+H]+:  found m/z 396.1543, calcd 396.1520 
3-(2,3-dihydroxypropoxy)-1-hydroxyacridin-9(10H)-one (11):  1-hydroxy-3-
(oxiran-2-ylmethoxy)acridin-9(10H)-one (0.25 mmol) was dissolved in 15 mL of 
20% aqueous NaOH and stirred at 70 °C for 16 hours.  The reaction was then 
cooled and concentrated.  The residue was taken up in EtOAc, washed with 
water, dried over Na2SO4 and concentrated in vacuo followed by purification on 
silica eluting 95:5 DCM:MeOH to yield the compound as a yellow solid.  78% 
yield.  1H-NMR (600 MHz, CD3OD):  δ 3.65-3.82 (m, 2H), 3.9-4.16 (m, 3H), 6.18 
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(s, 1H), 6.36 (s, 1H), 7.24 (t, J = 7.2 Hz, 1H), 7.40 (d, J = 8.4 Hz, 1H), 7.67 (t, J = 
8.4 Hz, 1H), 8.21 (d, J = 8.4 Hz, 1H); HRMS (C16H15NO5) [M-H]-:  found m/z 
300.0864, calcd 300.0877. 
1,3-bis(2,3-dihydroxypropoxy)acridin-9(10H)-one (12):  1,3-bis(oxiran-2-
ylmethoxy)-10-(oxiran-2-ylmethyl)acridin-9(10H)-one (0.15 mmol) was dissolved 
in 15 mL of 20% aqueous NaOH and stirred at 70 °C for 16 hours.  The reaction 
was then cooled and concentrated.  The residue was taken up in EtOAc, washed 
with water, dried over Na2SO4 and concentrated in vacuo followed by purification 
on silica eluting 95:5 DCM:MeOH to yield the compound as a yellow solid.  80% 
yield.  1H-NMR (600 MHz, DMSO-d6):  δ 3.44-3.58 (m, 4H), 3.81 (m, 1H), 4.00 
(m, 2H), 4.13 (m, 1H), 4.47 (m, 2H), 6.26 (s, 1H), 6.76 (s, 1H), 7.33 (t, J = 7.2 Hz, 
1H), 7.79 (t, J = 7.2 Hz, 1H), 7.96 (m, 1H), 8.29 (d, J = 7.8 Hz, 1H). HRMS 
(C19H21NO7) [M-H]-:  found m/z 374.1229, calcd 374.1234. 
1,3-dihydroxy-9H-xanthen-9-one (5):  Salicylic acid (36.2 mmol), phloroglucinol 
(55.5 mmol), and zinc (110 mmol) were dissolved in 35 mL of phosphorous 
oxychloride and stirred at 70 °C for 2 hours.  After 2 hours, the mixture was 
cooled and poured into ice water.  The resultant precipitate was collected via 
filtration, washed with water, and dried.  The compound was purified on silica 
eluting 4:1 Hex:EtOAc to yield the compound as a light yellow solid.  42% yield.  
1H-NMR (600 MHz, DMSO-d6):  δ 6.24 (d, J = 2.4 Hz, 1H), 6.38 (d, J = 2.4 Hz, 
1H), 7.45 (t, J = 7.2 Hz, 1H), 7.58 (d, J = 7.8 Hz, 1H), 7.84 (m, 1H), 8.12 (d, J = 
8.4 Hz, 1H), 11.09 (s, 1H), 12.80 (s, 1H);  HRMS (C13H8O4) [M-H]-:  found m/z 
227.0336, calcd 227.0350. 
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General procedure for mono and di-epoxy-xanthones:  1,3-dihydroxy-9H-
xanthen-9-one (0.88 mmol) and Cs2CO3 (1.31 mmol) was dissolved in 10 mL of a 
1:1 DMF:Acetone mixture.  Epibromohydrin (1.23 mmol) was added and the 
reaction was heated at 60 °C for 16 hours.  The reaction was cooled and diluted 
with water, then extracted with ethyl acetate.   The combined organics were 
washed with brine, dried over Na2SO4 and concentrated in vacuo.  The residue 
was purified on silica eluting 2:1 Hex:EtOAc to afford both the mono-epoxy and 
di-epoxy xanthone as pale yellow solids. 
1-hydroxy-3-(oxiran-2-ylmethoxy)-9H-xanthen-9-one (9):  40% yield.  1H-NMR 
(600 MHz, DMSO-d6):  δ 2.71 (m, 1H), 2.85 (t, J = 4.2 Hz, 1H), 3.35 (d, J = 2.4 
Hz, 1H), 3.96 (m, 1H), 4.50 (d, J = 11.4 Hz, 1H), 6.42 (s,, 1H), 6.66 (s, 1H), 7.46 
(t, J = 7.8 Hz, 1H), 7.59 (d, J = 8.4 Hz, 1H), 7.86 (t, J = 8.4 Hz, 1H),  8.13 (d, J = 
7.8 Hz, 1H); HRMS (C16H12O5) [M-H]-:  found m/z 283.0632, calcd 283.0612. 
1,3-bis(oxiran-2-ylmethoxy)-9H-xanthen-9-one (10):  47% yield.  1H-NMR (600 
MHz, DMSO-d6):  δ 2.72 (m, 1H), 2.85 (m, 2H), 3.02 (m, 1H), 3.37 (m, 2H), 3.96 
(m, 1H), 4.03 (m, 1H), 4.43 (d, J = 11.4 Hz, 1H), 4.50 (d, J = 11.4 Hz, 1H) 6.53 
(s, 1H), 6.70 (s, 1H), 7.38 (t, J = 7.2 Hz, 1H), 7.48 (d, J = 8.4 Hz, 1H), 7.73 (t, J = 
7.2 Hz, 1H),  8.05 (d, J = 7.8 Hz, 1H).  HRMS (C19H16O6) [M-H]-:  found m/z 
341.1052, calcd 341.1020. 
Methyl-2-iodobenzoate (14):  2-iodobenzoic acid (20.16 mmol) was dissolved in 
50mL DMF and 1.2 eq. of potassium carbonate (24.19 mmol) was added.  This 
mixture was stirred at room temperature for 30 min.  1.2 eq of methyl iodide 
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(24.19 mmol) was then added drop wise and this mixture was stirred at room 
temp for 1 hour.  The reaction mixture was diluted in 250mL of diethyl ether and 
washed 3x250mL of water.  The organic layer concentrated to afford 5.16g of a 
yellowish oil (19.69 mmol).  98% yield.  1H NMR (400 MHz, DMSO-d6) δ 3.85 (s, 
3H), 7.26 (td, J = 7.7, 1.7 Hz, 1H), 7.49 (td, J = 7.6, 1.2 Hz, 1H), 7.70 (dd, J = 7.8, 
1.8 Hz, 1H), 8.00 (dd, J = 7.9, 1.1, 1H). 
General Procedure for (2-methoxyphenylamino)benzoates:  Compounds 
were prepared by a modified procedure found in the literature.7  (Pd(OAc)2 (3 
mol%), dpff (6 mol%) and p-anisidine (45.5 mmol) were dissolved in 100 mL dry 
toluene and stirred under argon at 95 °C for 15 min.  After 15 min, methyl-2-
iodobenzoate (38 mmol) and Cs2CO3 (53.2 mmol) were added.  The reaction 
mixture was stirred at 95° C for 10 hours.  After cooling, the reaction was filtered 
and concentrated in vacuo.  The resultant oil was adsorbed on celite and purified 
on silica eluting 10% EtOAc:Hexanes to 20% EtOAc:Hexanes to afford the 
compounds as yellow oils.    
Methyl-2-(4-methoxyphenylamino)benzoate:  99% yield.  1H NMR (400 MHz, 
CDCl3) δ 3.82 (s, 3H), 3.90 (s, 3H), 6.66 (t, J = 7.3 Hz, 1H), 6.88-6.93 (m, 2H), 
6.97 (d, J = 8.6 Hz, 1H), 7.15-7.19 (m, 2H), 7.25 (m, 1H), 7.94 (dd, J = 8.0, 1.6 
Hz, 1H), 9.26 (br, s, 1H). 
Methyl-2-(2-methoxyphenylamino)benzoate:  Yield not determined and 
compound not characterized due to flask breaking in the hood.  The yellow oil 
was recovered from the bottom of the hood and carried on without re-purification. 
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2-(2-methoxyphenylamino)benzoic acid (15a):  An unknown amount of 
methyl-2-(2-methoxyphenylamino)benzoate was dissolved in 500 mL of acetone.  
350 mL of 5% NaOH was added and the reaction was stirred at room 
temperature overnight.  The reaction was then neutralized with 3N HCl and the 
organics were removed under reduced pressure.  The resultant yellow solid was 
collected via filtration and washed 2x with 150mL water to yield 7.50 g of 
orangeish-yellow solid.  Yield not determined.  1H NMR (400 MHz, DMSO-d6) δ 
3.82 (s, 3H), 6.76 (t, J = 7.4 Hz, 1H), 6.94 (m, 1H), 7.01-7.11 (m, 2H), 7.19 (d, J = 
8.2 Hz, 1H), 7.34-7.41 (m, 2H), 7.89 (dd, J = 7.9, 1.5 Hz, 1H), 9.58 (s, 1H), 12.97 
(br, s, 1H). 
2-(4-methoxyphenylamino)benzoic acid (15b):  
Methyl-2-(4-methoxyphenylamino)benzoate (37.53 mmol) was dissolved in 500 
mL of acetone.  350 mL of 5% NaOH was added and the reaction was stirred at 
room temperature overnight.  The reaction was then neutralized with 3N HCl and 
the organics were removed under reduced pressure.  The resultant yellow solid 
was collected via filtration and washed 2x with 150mL water to yield 8.02g (32.97 
mmol) of yellow solid.    88% yield.  1H NMR (400 MHz, DMSO-d6) δ 3.76 (s, 3H), 
6.68 (t, J = 7.6 Hz, 1H), 6.89-6.99 (m, 3H), 7.15-7.21 (m, 2H), 7.32 (ddd, J = 8.6, 
7.0, 1.7 Hz, 1H), 7.86 (dd, J = 7.9, 1.7 Hz, 1H), 9.43 (br, s, 1H), 12.94 (br, s, 1H). 
2-methoxy-9-phenoxyacridine (19a): Compound was synthesized using 
previously published procedures.103  76% yield.  1H NMR (600 MHz, CDCl3) δ 
3.81 (s, 3H), 6.87 (d, J = 8.8 Hz, 2H), 7.05 (t, J = 7.6 Hz, 1H), 7.19 (d, J = 2.9 Hz, 
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1H), 7.25-7.29 (m, 2H), 7.41-7.48 (m, 2H), 7.71 (m, 1H), 8.03 (d, J = 8.8 Hz, 1H), 
8.15 (d, J = 9.4 Hz, 1H), 8.23 (d, J = 8.8 Hz, 1H). 
4-methoxy-9-phenoxyacridine (19b):  Compound was synthesized using 
previously published procedures.103  91% yield.  1H NMR (400 MHz, CDCl3) δ 
4.17 (s, 3H), 6.83 (dd, J = 8.7, 0.9 Hz, 2H), 7.00-7.08 (m, 2H), 7.22-7.30 (m, 2H), 
7.36 (dd, J = 8.7, 7.5 Hz, 1H), 7.46 (ddd, J = 8.6, 6.7, 1.0 Hz, 1H), 7.66 (dd, J = 
8.6, 1.0 Hz, 1H), 7.76 (ddd, J = 8.6, 6.8, 1.4 Hz, 1H), 8.08 (d, J = 8.6 Hz, 1H), 
8.43 (d, J = 8.8 Hz, 1H). 
2-hydroxy-9-phenoxyacridine (20):  3.1 g (10 mmol) of 2-methoxy-9-
phenoxyacridine was dissolved in DCM and placed under nitrogen.  4.75 mL (50 
mmol) of boron tribromide was added via syringe and the reaction mixture was 
stirred at room temperature overnight.  The reaction was then cooled in an ice 
bath and carefully quenched with saturated sodium bicarbonate until the 
evolution of gas ceased and the aqueous phase was at pH 7.0.  The aqueous 
phase was extracted with DCM and the combined organics were concentrated 
and purified on silica eluting 10% MeOH:DCM to afford the product as a light 
yellow solid.  63% yield.  1H NMR (400 MHz, DMSO-d6) δ 6.82-6.89 (m, 2H), 7.07 
(t, J = 7.5 Hz, 1H), 7.15 (d, J = 2.5 Hz, 1H), 7.28-7.36 (m, 2H), 7.45-7.57 (m, 2H), 
7.76 (m, 1H), 7.94 (dd, J = 8.7, 0.6 Hz, 1H), 8.12 (d, J = 9.4 Hz, 1H), 8.16 (d, J = 
8.8 Hz, 1H), 10.33 (br, s, 1H); HRMS (C19H14NO2) [M+H]+:  found m/z 288.1021, 
calcd 288.1019. 
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4-hydroxy-9-phenoxyacridine (21):  Compound was synthesized following the 
same procedure as compound 20.  68% yield.  1H NMR (400 MHz, DMSO-d6) δ 
6.83-6.90 (m, 2H), 7.06 (m, 1H), 7.14 (dd, J = 6.2, 2.2 Hz, 1H), 7.28-7.34 (m, 
2H), 7.37-7.45 (m, 2H), 7.59 (ddd, J = 8.7, 6.7, 1.1 Hz, 1H), 7.87 (m, 1H), 8.02 (d, 
J = 8.6 Hz, 1H), 8.28 (d, J = 8.8 Hz, 1H), 10.03 (s, 1H); HRMS (C19H14NO2) 
[M+H]+:  found m/z 288.1028, calcd 288.1019. 
2-(1-methyl-1H-indol-3-yl)-ethanamine:  Compound was prepared and purified 
according to literature procedures131.  
General Procedure for 9-alkylamino-hydroxy acridines:  280 mg (1 mmol) of 
4-hydroxy-9-phenoxyacridine and 156 mg (1.2 mmol) of octylamine were 
dissolved in excess phenol and stirred at 100 °C for 1 hour.  Upon cooling, the 
reaction was diluted in EtOAc and purified on silica eluting 25% MeOH:EtOAc to 
afford the product as a reddish orange solid. 
9-(octylamino)acridin-2-ol (22a):  1H NMR (400 MHz, (CD3)2CO) δ 0.84 (t, J = 
6.5 Hz, 3H), 1.16-1.34 (m, 8H), 1.41 (quin, J = 7.1 Hz, 2H), 1.80 (quin, J = 7.4 
Hz, 2H), 3.80 (t, J = 7.2 Hz, 2H), 7.36 (m, 1H), 7.44 (dd, J = 9.4, 2.0 Hz, 1H), 
7.62 (m, 1H), 7.69 (d, J = 2.0 Hz, 1H), 7.96 (m, 2H), 8.33 (d, J = 9.0 Hz, 1H); 
HRMS (C21H27N2O) [M+H]+:  found m/z 323.2117, calcd 323.2118. 
9-(2-(1-methyl-1H-indol-3-yl)ethylamino)acridin-2-ol (22b): 1H NMR (400 
MHz, DMSO-d6) δ 3.27 (t, J = 7.4 Hz, 2H), 3.69 (s, 3H), 4.27 (t, J = 7.0 Hz, 2H), 
6.96 (t, J = 7.4 Hz, 1H), 7.11 (t, J = 7.4 Hz, 1H), 7.19 (s, 1H), 7.35 (d, J = 8.2 Hz, 
1H), 7.43 (t, J = 7.4 Hz, 1H), 7.52-7.62 (m, 2H), 7.79 -7.92 (m, 4H), 8.49 (d, J = 
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8.6 Hz, 1H), 10.30 (br, s, 1H); HRMS (C24H23N3O) [M+H]+:  found m/z 368.1747, 
calcd 368.1757. 
9-(1-benzylipiperidin-4-ylamino)-acridin-2-ol (22c):  1H NMR (400 MHz, 
DMSO-d6) δ 1.78-2.00 (m, 6H), 2.80 (d, J = 10.8 Hz, 2H), 3.43 (s, 2H), 3.65 (br, 
s, 1H), 6.21 (br, s, 1H), 7.18-7.32 (m, 5H), 7.37 (m, 2H), 7.49 (d, J = 2.0 Hz, 1H), 
7.61 (t, J = 7.5 Hz, 1H), 7.84 (t, J = 10.0 Hz, 2H), 8.30 (d, J = 8.6 Hz, 1H), 9.90 
(br, s, 1H); HRMS (C25H26N3O) [M+H]+:  found m/z 384.2063, calcd 384.2070. 
9-(octylamino)acridin-4-ol (22d):  1H NMR (400 MHz, CDCl3) δ 0.87 (t, J = 6.8 
Hz, 3H), 1.20-1.39 (m, 8H), 1.45 (quin, J = 7.3 Hz, 2H), 1.79 (m, 2H), 3.86 (m, 
2H), 5.16 (s, 1H), 5.90 (br, s, 1H), 7.10 (d, J = 7.2 Hz, 1H), 7.26 (m, 1H), 7.37 (t, 
J = 7.5 Hz, 1H), 7.53 (d, J = 8.8 Hz, 1H), 7.66 (m, 1H), 8.04 (d, J = 8.6 Hz, 1H), 
8.10 (d, J = 8.6 Hz, 1H); HRMS (C21H27N2O) [M+H]+:  found m/z 323.2119, calcd 
323.2118. 
9-(2-(1-methyl-1H-indol-3-yl)ethylamino)acridin-4-ol (22e): 1H NMR (400 
MHz, CDCl3) δ 3.24 (t, J = 6.6 Hz, 2H), 3.77 (s, 3H), 4.25 (t, J = 6.6 Hz, 2H), 5.56 
(br, s, 1H), 6.93 (s, 1H), 7.10 (d, J = 7.4 Hz, 1H), 7.15-.722 (m, 2H), 7.30 (m, 2H), 
7.37 (m, 2H), 7.65 (m, 2H), 7.96 (d, J = 8.8 Hz, 1H), 8.04 (d, J = 8.8 Hz, 1H); 
HRMS (C24H23N3O) [M+H]+:  found m/z 368.1754, calcd 368.1757. 
9-(1-benzylipiperidin-4-ylamino)-acridin-4-ol (22f):  1H NMR (400 MHz, CDCl3) 
δ 1.69-1.80 (m, 2H), 2.04-2.16 (m, 4H), 2.85-2.91 (m, 2H), 3.52 (s, 2H), 3.94 (br, 
s, 1H), 4.79 (br, s, 1H), 7.12 (d, J = 7.2 Hz, 1H), 7.26 (m, 1H), 7.28-7.35 (m, 5H), 
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7.43 (t, J = 7.5 Hz, 1H), 7.50 (d, J = 9.0 Hz, 1H), 7.69 (m, 1H), 8.08 (t, J = 7.5 Hz, 
2H); HRMS (C25H26N3O) [M+H]+:  found m/z 384.2066, calcd 384.2070. 
General Procedure for 2-epoxy acridines:  325 mg (1 mmol) of 9-
(octylamino)acridin-2-ol was dissolved in 40 mL 1:1 DMF:MeCN and 650 mg (2 
mmol) Cs2CO3 was added.  The mixture was stirred at 70 °C for 10 min.  165 mg 
(1.2 mmol) of epibromohydrin was added and the reaction was stirred at 70 °C 
for 12 hours.  Upon cooling, the reaction was passed through a plug of celite and 
solvent was removed by rotary evaporation.  The residue was purified on silica 
eluting 20:80 MeOH:EtOAc to 20:75:5 MeOH:EtOAc:Et3N.  Collected fractions 
were concentrated, taken up into DCM and precipitated with hexanes to afford 
the compound as a yellow solid. 
N-octyl-2-(oxiran-2-ylmethoxy)-acridin-9-amine (23) 1H NMR (400 MHz, 
CDCl3) δ 0,89 (m, 3H), 1.24-1.48 (m, 8H), 1.56 (m, 2H), 2.07 (m, 2H), 2.90 (dd, J 
= 4.8, 2.6 Hz, 1H), 2.97 (m, 1H), 3.40 (m, 1H), 4.04-4.15 (m, 3H), 4.63 (d, J = 
11.7 Hz, 1H), 6.81 (d, J = 8.6 Hz, 1H), 7.28 (m, 1H), 7.56 (m, 1H), 7.62 (t, J = 7.7 
Hz, 1H), 7.68 (d, J = 9.4 Hz, 1H), 8.07 (dd, J = 11.7, 9.0 Hz, 2H); HRMS 
(C24H31N2O2) [M+H]+:  found m/z 379.2385, calcd 379.2380. 
N-(2-(1-methyl-1H-indol-3-yl)ethyl)-2-(oxiran-2-ylmethoxy)acridin-9-amine 
(24)  1H NMR (400 MHz, (CD3)2CO) δ  2.72 (dd, J = 5.1, 2.5 Hz, 1H), 2.86 (dd, J 
= 5.1, 4.3 Hz, 1H), 3.22 (t, J = 7.1 Hz, 2H), 3.35 (qd, J = 4.4, 2.7 Hz, 1H), 3.73 (s, 
3H), 3.88 (dd, J = 11.2, 6.3 Hz, 1H), 4.14 (t, J = 7.1 Hz, 2H), 4.28 (dd, J = 11.1, 
2.8 Hz, 1H), 7.01 (m, 1H), 7.06 (s, 1H), 7.15 (m, 2H), 7.36 (m, 2H), 7.41 (dd, J = 
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9.4, 2.7 Hz, 1H), 7.51 (s, 1H), 7.58 (d, J = 8.0 Hz, 1H), 7.63 (ddd, J = 8.5, 6.8, 1.4 
Hz, 1H), 7.96 (m, 2H), 8.29 (d, J = 8.2 Hz, 1H); HRMS (C27H26N3O2) [M+H]+:  
found m/z 424.2017, calcd 424.2020. 
N-(1-benzylpiperidin-4-yl)-2-(oxiran-2-ylmethoxy)acridin-9-amine (25) 1H 
NMR (400 MHz, CDCl3) δ 1.70-1.79 (m, 2H), 1.99-2.09 (m, 4H), 2.83-2.92 (m, 
3H), 2.99 (t, J = 4.4 Hz, 1H), 3.50 (s, 2H), 3.72 (br, s, 1H), 4.09 (dd, J = 10.6, 5.9 
Hz, 1H), 4.36 (d, J = 10.6 Hz, 1H), 4.41 (d, J = 11.2 Hz, 1H), 7.26 (m, 1H), 7.28-
7.34 (m, 5H), 7.41-7.48 (m, 2H), 7.66 (t, J = 7.3 Hz, 1H), 8.03-8.08 (m, 2H), 8.11 
(d, J = 8.8 Hz, 1H); HRMS (C28H30N3O2) [M+H]+:  found m/z 440.2337, calcd 
440.2333. 
3-((9-phenoxyacridin-2-yl)oxy)propane-1,2-diol (26):  280 mg (1 mmol) of 2-
hydroxy-9-phenoxyacridine was dissolved in 40 mL 1:1 DMF:MeCN and 650 mg 
(2 mmol) Cs2CO3 was added.  The mixture was stirred at 70 °C for 10 min.  133 
mg (1.2 mmol) of 3-chloro-1,2-propanediol was added and the reaction was 
stirred at 70 °C for 12 hours.  Upon cooling, the reaction was passed through a 
plug of celite and solvent was removed by rotary evaporation.  The residue was 
passed through a silica plug eluting 20:80 MeOH:EtOAc and carried on without 
further purification.   
3-((9-phenoxyacridin-4-yl)oxy)propane-1,2-diol (27):  Followed the same 
procedure for 3-((9-phenoxyacridin-2-yl)oxy)propane-1,2-diol. 
3-(9-(octylamino)acridin-2-yl)oxy)propane-1,2-diol (28) 1H NMR (400 MHz, 
CDCl3) δ 0.87 (t, J = 6.8 Hz, 3H), 1.19-1.35 (m, 8H), 1.40 (m, 2H), 1.73 (quin, J = 
75 
 
7.3 Hz, 2H), 3.66 (t, J = 7.2 Hz, 2H), 3.86 (m, 1H), 3.93 (m, 1H), 4.15-4.25 (m, 
3H), 4.79 (br, s, 2H), 7.21 (d, J = 2.5 Hz, 1H), 7.29 (dd, J = 9.5, 2.4 Hz, 1H), 7.40 
(m, 1H), 7.65 (m, 1H), 7.97 (d, J = 9.4 Hz, 1H), 8.07 (t, J = 9.8 Hz, 2H); HRMS 
(C24H33N2O3) [M+H]+:  found m/z 397.2491, calcd 397.2486. 
3-(9-(2-(1-methyl-1H-indol-3-yl)ethylamino)acridin-2-yl)oxy)propane-1,2-diol 
(29) 1H NMR (400 MHz, DMSO-d6) δ 3.11 (t, J = 7.6 Hz, 2H), 3.53 (t, J = 5.1 Hz, 
2H), 3.68 (s, 3H), 3.90 (m, 1H), 3.97-4.07 (m, 3H), 4.15 (dd, J = 9.9, 4.2 Hz, 1H), 
4.75 (t, J = 5.5 Hz, 1H), 5.05 (d, J = 5.1 Hz, 1H), 6.98 (t, J = 7.4 Hz, 1H), 7.08-
7.14 (m, 2H), 7.29-7.37 (m, 2H), 7.41 (d, J = 9.0 Hz, 1H), 7.52 (d, J = 8.0 Hz, 
1H), 7.58-7.66 (m, 2H), 7.78-7.90 (m, 2H), 8.30 (d, J = 8.8 Hz, 1H); HRMS 
(C27H28N3O3) [M+H]+:  found m/z 442.2107, calcd 442.2125. 
3-(9-(1-benzylpiperidin-4-ylamino)acridin-2-yl)oxy)propane-1,2-diol (30) 1H 
NMR (400 MHz, CDCl3) δ 1.70-1.82 (m, 2H), 1.95-2.10 (m, 4H), 2.85-2.93 (m, 
2H), 3.51 (s, 2H), 3.71 (br, s, 1H), 3.84-3.98 (m, 2H), 4.16-4.27 (m, 3H), 4.57 (br, 
s, 2H), 7.21 (d, J = 2.5 Hz, 1H), 7.28-7.36 (m, 5H), 7.43 (t, J = 7.9 Hz, 1H), 7.67 
(t, J = 7.5 Hz, 1H), 7.99 (d, J = 9.4 Hz, 1H), 8.04 (d, J = 8.8 Hz, 1H), 8.11 (d, J = 
8.6 Hz, 1H); HRMS (C28H32N3O3) [M+H]+:  found m/z 458.2442, calcd 458.2438. 
3-(9-(octylamino)acridin-4-yl)oxy)propane-1,2-diol (31) 1H NMR (400 MHz, 
CDCl3) δ 0.88 (t, J = 6.7 Hz, 3H), 1.21-1.40 (m, 8H), 1.46 (m, 2H), 1.81 (m, 2H), 
1.81 (quin, J = 7.1 Hz, 2H), 3.87 (t, J = 7.4 Hz, 2H), 3.93 (m, 2H), 4.14 (m, 1H), 
4.27 (dd, J = 10.0, 5.7, 1H), 4.45 (dd, J = 10.0, 2.5 Hz, 1H), 5.37 (br, s, 2H), 7.20 
(m, 1H), 7.29 (m, 1H), 7.36 (t, J = 7.3 Hz, 1H), 7.66 (m, 1H), 7.78 (d, J = 8.6 Hz, 
76 
 
1H), 8.08 (d, J = 8.8 Hz, 1H), 8.13 (d, J = 8.6 Hz, 1H); HRMS (C24H33N2O3) 
[M+H]+:  found m/z 397.2505, calcd 397.2486. 
3-(9-(2-(1-methyl-1H-indol-3-yl)ethylamino)acridin-4-yl)oxy)propane-1,2-diol 
(32) 1H NMR (400 MHz, (CD3)2CO) δ 3.28 (t, J = 7.1 Hz, 2H), 3.68-3.82 (m, 5H), 
4.04 (m, 1H), 4.20-4.29 (m, 3H), 4.31 (m, 1H), 7.00 (t, J = 7.4 Hz, 1H), 7.10 (s, 
1H), 7.14 (m, 1H), 7.18-7.36 (m, 4H), 7.58-7.68 (m, 2H), 7.92-8.01 (m, 2H), 8.29 
(d, J = 8.6 Hz, 1H); HRMS (C27H28N3O3) [M+H]+:  found m/z 442.2146, calcd 
442.2125. 
3-(9-(1-benzylpiperidin-4-ylamino)acridin-4-yl)oxy)propane-1,2-diol (33) 1H 
NMR (400 MHz, CDCl3) δ 1.76 (m, 2H), 2.01-2.15 (m, 4H), 2.88 (d, J = 11.8 Hz, 
2H), 3.52 (s, 2H), 3.84-3.98 (m, 3H), 4.13 (m, 1H), 4.29 (dd, J = 10.0, 5.5 Hz, 
1H), 4.48 (dd, J = 9.9, 2.4 Hz, 1H), 4.79 (br, s, 2H), 7.26 (m, 2H), 7.29-7.36 (m, 
5H), 7.43 (t, J = 7.5 Hz, 1H), 7.66-7.76 (m, 2H), 8.05 (d, J = 8.4 Hz, 1H), 8.16 (d, 
J = 8.8 Hz, 1H); HRMS (C28H32N3O3) [M+H]+:  found m/z 458.2442, calcd 
458.2440. 
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Chapter 5:  Synthesis of Bis-Acridines and Cytotoxic Evaluation in the 
DU145 Prostate Cancer Cell Line 
 
Introduction 
DNA is a well known and well studied target for the development of potential 
novel anti-cancer therapies.  There are numerous ways in which drugs can 
interact with DNA and exert their anti-cancer effects.  Cross-linking agents such 
as Mitomycin C136 and Cisplatin137 alkylate two complimentary DNA strands, 
prevent DNA replication, and lead to cell death.  DNA groove binders such as 
Distamycin A exert their cytotoxic effects by non-covalently binding the minor 
groove and preventing gene transcription or DNA replication.138  There are drugs 
that cause DNA damage via cleaving the DNA strand, drugs that incorporate into 
the replicating DNA that block chain elongation, and drugs that intercalate DNA, 
interfering with the enzymes responsible for modifying the topology of DNA and 
replicating it.139  It is the last class, the intercalators, that has received the most 
attention over the years and is the class of compounds that the acridines belong 
to. 
Acridines are tri-cyclic, planar heterocycles that reversibly bind DNA via 
intercalation.140  The 9-amino acridines are cationic at physiological pH which 
enhances their binding to the DNA backbone via ionic interaction between the 
positively charged nitrogen of the acridine and the negatively charged phosphate 
backbone of the DNA.141  The acridines previously described by our laboratory 
act via DNA intercalation that interferes with the catalytic cycle of topoisomerase 
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II.115  Despite their effectiveness, acridines still have numerous downsides such 
as high toxicity due to non-specific intercalation142 and short lived complexes with 
the DNA.143  One strategy to enhance the binding of acridines to DNA and form 
longer lived complexes with potentially a higher degree of selectivity is to link two 
acridines into a complex capable of bis-intercalation.144,145   
The first bis-intercalator discovered, echinomycin, is a symmetrical peptide anti-
biotic with two quinoxaline chromophores.  Evidence that suggested echinomycin 
was a bis-intercalator came from research comparing the perturbation of the 
DNA helix compared to a known mono-intercalator and it was found to cause the 
helix to extend twice of what would be expected for a mono-intercalating 
agent.146  This discovery has spurred numerous studies into trying to enhance 
the potency and selectivity of intercalative drugs by linking them in a manner that 
would allow for bis-intercalation.147   
Following the principles on bis-intercalation found in these numerous studies, we 
set out to link together our most promising acridine chromophores in a manner 
that would hopefully lead to them becoming bis-intercalating anti-cancer agents.  
To do this, we chose a simple symmetrical di-amine starting with a linker length 
of six atoms.  This length was chosen as it has been reported that it is the 
minimum linker length that would facilitate bis-intercalation without violating the 
neighbor exclusion principal, which states two intercalators cannot intercalate 
between adjacent base pairs.147  Along with the bis-acridines, we needed a set of 
control analogs that lack the second chromophores yet retain a similar linker.  To 
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accomplish this, we decided the best control molecules would be the acridine 
core with the appropriate length alkylamine at the 9-position. 
 
Synthesis 
 
Shown in Scheme 5, synthesis of the bis-acridines and their controls started with 
construction of the acridine core itself.  To accomplish this, I followed work 
previously pioneered in our lab by Dr. John Goodell that utilized an Ullmann-
Jourdan condensation between 2-bromoterephthalic acid 1 and aniline 2 to afford 
2-phenylaminoterephthalic acid 3.  Tandem cyclization and acyl chloride 
formation in refluxing phosphorus oxychloride gave us intermediate 4 which was 
immediately reacted with N-methylpiperizine yielding a 9-chloro-3-carboxamide 
acridine that was converted to its more stable 9-phenoxy-3-carboxamide acridine 
5 by reaction with molten phenol.  With our intermediate in hand for the synthesis 
of all the analogs, our first attempts to synthesize the bis-acridines were 
unsuccessful.   Ideally we would have been able to continue following the 
methodology previously developed in our lab, however due to the nature of the 
bis-acridine, precise control over the equivalents of acridine and amine are vital 
to the success of the synthesis.  This meant that running the reaction neat was 
not a viable route due to the small amount of di-amine needed.   This lead us to 
try a number of solvents ranging from dichloromethane to xylenes across the 
range of their boiling points.  None of these reaction conditions afforded our 
desired bis-acridine products due to no reaction occurring when followed by 
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mass spec.  Eventually it was found that using phenol as the solvent with a ratio 
of 2.1 equivalents of acridine to 1 equivalent of di-amine gave low to moderate 
yields of the bis-acridines 6-9.  The corresponding control acridines 10-13 were 
synthesized as described in chapter 2.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 5:  Synthesis of Bis-Acridines and controls:  Reagents and 
conditions:  (a) Cu, CuI, Pyridine, K2CO3, H2O, reflux, 4h; (b) POCl3, reflux, 2h; 
(c) i. N-methylpiperizine, DCM, 0 °C to rt, 1h, ii.  Phenol, 80 °C, 2h; (d) amine, 
phenol, 100 °C, 1-4h. 
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Biological Evaluation 
With the desired bis-acridines and controls in hand, we tested the compounds for 
their cytotoxic activity against the DU145 prostate cancer cell line using a Cell 
Titer-Blue® assay.148 
 
Results and Discussion 
Shown in Table 4 are the cytotoxicity results for the 8 compounds synthesized 
and tested in this study.  This bis-acridines 6-9 showed increasing activity with 
the increase in linker length between the acridine chromophores.  This result was 
as expected, as we hypothesized the longer the linker, the more likely the 
compound would be to bis-intercalate and be more potent.  When comparing the 
cytotoxicity to the control acridines 10-13, the compounds showed the same 
trend in increasing cytotoxicity with substituent length, however there was not a 
marked loss in activity when compared to the respective bis-acridine compound.  
This suggests to us that linking our 3-carboxamide acridines confers no 
advantages over using a simple alkylamine in the 9 position. 
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One possible explanation to this is the position of our carboxamide group.  In 
previously published studies, the 1,8-diaminooctane linker gave the biggest 
increase in potency over the monomeric acridine, however in all of these studies, 
the acridine had a 4-carboxamide group instead of the 3-carboxamide group we 
have.143,144  One caveat of this is their monomeric controls were just the un-
substituted 9-amino-4-carboxamide acridine.  When we compare our data in 
which our controls were much more similar to the bis-compounds than in 
previously published studies, the nature of the 9-amino substituent may be more 
important and over-ride any effects gained from having a bis-intercalator.  Further 
work on our compounds determining the DNA binding constants would provide 
more insight into the importance of having the bis-acridine instead of the simple 
DU145 Prostate Cancer Cell Cytotoxicity 
Compound n = EC50  (µM) Compound n = EC50  (µM) 
6 4 > 100 10 4 28.48 ± 2.62 
7 5 50.20 ± 0.67 11 5 19.13 ± 6.76 
8 6 17.01 ± 3.98 12 6 14.22 ± 3.68 
9 7 9.22 ± 1.67 13 7 6.42 ± 1.29 
Table 4:  Cytotoxicity results for the bis and control acridines 
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9-alkylamino acridine.  Perhaps the bis-compounds do bind DNA more tightly 
with a longer lasting complex in a manner that does not increase their potency, 
however decreases their general toxicity due to non-specific binding. 
 
Experimental 
1.  Cytotoxicity Assay 
DU145 cells were cultured in RPMI-1640 media supplemented with 10% fetal 
bovine serum (FBS) and 1% penicillin/streptomycin (pen/strep).  After reaching 
confluency, cells were treated with trypsin, pelletized, and re-suspended in 
growth media.  Cell concentration was determined via counting on a 
hemocytometer and then cells were plated at a concentration of 5000 cells per 
well and left to incubate for 24 hours.  After 24 hours, growth media was removed 
and the cells were treated with fresh growth media containing 2% DMSO and the 
compounds starting at 100 µM with a 2 fold dilution factor over 8 wells in 
triplicate.  The treated cells were incubated for 48 hours then viability was tested 
using the Cell Titer-Blue® assay.  Dose response curves and EC50 values were 
calculated using GraphPad Prism 4.0.  The assays were repeated on three 
consecutive days. 
2. Synthesis 
Compounds 3, 4, and 5 were prepared according to previously published 
procedures.103 
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General Procedure for Synthesis of Bis-Acridines:  (4-methylpiperazin-1-
yl)(9-phenoxyacridin-3-yl)methanone (2.2 mmol) was dissolved in 10g of molten 
phenol.  1,6-diaminohexane (1.0 mmol) was added and the reaction was stirred 
at 100 °C for 4 hours.  The reaction was then cooled, dissolved in 
dichloromethane, and purified on silica eluting 10% MeOH:DCM to 10% 
MeOH:DCM with 1% triethylamine.  The purified product was dissolved in ethyl 
acetate and precipitated with hexanes to afford the desired compounds as 
orange solids. 
((nonane-1,9-diylbis(azanediyl))bis(acridine-9,3-diyl))bis((4-methylpiperazin-
1-yl)methanone) (6). Yield:  31%; 1H NMR (600 MHz, CD3OD) δ 1.19 (m, 6H), 
1.31 (m, 4H), 1.79 (quin ,J = 7.3 Hz, 4H), 2.34 (s, 6H), 2.44 (br, s, 4H), 2.56 (br, 
s, 4H), 3.53 (br, s, 4H), 3.83 (br, s, 4H), 3.93 (t, J = 7.2 Hz, 4H), 7.37 (dd, J = 1.6, 
9.0 Hz, 2H), 7.41 (m, 2H), 7.75 (ddd, J = 1.3, 6.9, 8.5 Hz, 2H), 7.83 (m 4H), 8.34 
(d, J = 8.8 Hz, 2H), 8.44 (d, J = 9.1 Hz, 2H). 
((octane-1,8-diylbis(azanediyl))bis(acridine-9,3-diyl))bis((4-methylpiperazin-
1-yl)methanone) (7).  Yield:  26%; 1H NMR (600 MHz, CD3OD) δ 1.21 (m, 4H), 
1.28 (m, 4H), 1.74 (quin, J = 7.0, 4H), 2.32 (s, 6H), 2.43 (br, s, 4H), 2.56 (br, s, 
4H), 3.53 (br, s, 4H), 3.83 (br, s, 4H), 3.87 (t, J = 7.0, 4H), 7.32-7.39 (m, 4H), 
7.71 (t, J = 7.6 Hz, 2H), 7.81-7.86 (m, 4H), 8.30 (d, J = 8.8 Hz, 2H), 8.39 (d, J = 
8.8 Hz, 2H). 
((heptane-1,7-diylbis(azanediyl))bis(acridine-9,3-diyl))bis((4-
methylpiperazin-1-yl)methanone) (8).  Yield:  38%; 1H NMR (600 MHz, 
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CD3OD) δ 1.22-1.32 (m, 6H), 1.70 (m, 4H), 2.31 (s, 6H), 2.41 (br, s, 4H), 2.55 (br, 
s, 4H), 3.53 (br, s, 4H), 3.75-3.88 (m, 8H), 7.28-7.35 (m, 4H), 7.66 (t, J = 7.6 Hz, 
2H), 7.82-7.87 (m, 4H), 8.25 (d, J = 8.8 Hz, 2H), 8.35 (d, J = 8.8 Hz, 2H). 
((hexane-1,6-diylbis(azanediyl))bis(acridine-9,3-diyl))bis((4-methylpiperazin-
1-yl)methanone) (9).  Yield:  34%; 1H NMR (600 MHz, CD3OD) δ 1.40 (m, 4H), 
1.77 (t, J = 6.7 Hz, 4H), 2.32 (s, 6H), 2.42 (br, s, 4H), 2.57 (br, s, 4H), 3.53 (br, s, 
4H), 3.77-3.90 (m, 8H), 7.28-7.34 (m, 4H), 7.67 (m, 2H), 7.83-7.87 (m, 4H), 8.25 
(d, J = 8.5 Hz, 2H), 8.36 (d, J = 8.8 Hz, 2H). 
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Chapter 6:  Acridine Epoxides; Failures, Lessons, and What Led to the 
Change in Substitution Pattern 
After we had synthesized and tested the acridone and xanthone epoxides and 
found them to be active against MRSA, we set out to synthesize the analogous 
acridine epoxides following the same substitution pattern seen in Figure 16. 
 
 
 
 
 
The original synthetic plan for the acridine epoxides called for placing the 
epoxide groups off hydroxyls located in the 1-, 3-, or both positions of the 
acridines.  We envisioned the most direct route to the desired analogs was via 
synthesis of the appropriate hydroxy acridines followed by alkylation using 
epibromohydrin or epichlorohydrin.   
Shown in Scheme 6, the synthesis started with an Ullmann coupling between m-
anisidine 1 and 2-chlorobenzoic acid 2 to afford the coupling product 3 which was 
then cyclize in refluxing phosphorous oxychloride to afford a mixture of 9-chloro-
1-methoxy acridine 4 and 9-chloro-3-methoxy acridine 5 which were converted to 
their more stable 9-phenoxy acridine derivatives 6-7 by heating in molten phenol 
at 80 °C for 2 hours.  The two isomers produced were separable by flash 
 
Figure 16:  Example acridone epoxide (left) and acridine 
epoxide (right). 
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chromatography on silica and gave roughly a 9:1 mix of the 3-substituted product 
to the 1-substiuted product.  Due to the yield of the 1-substituted product being 
so low, it was set aside and it was decided that most of our work would 
concentrate on the 3-methoxy acridine. 
Reaction of the 9-phenoxy-3-methoxy acridine with either 1-decylamine, 
tryptamine, or 4-amino-1-benzyl piperidine afforded our 9-amino analogs 9-11.  
Demethylation with boron tribromide was successful in the case of the 1-
decylamine and tryptamine analogs 9 and 10, however was unsuccessful in the 
case of the 4-amino-1-benzyl piperidine analog 11.  Demethylation attempts of 
compound 11 all led to complex mixtures of compounds, none of which were our 
desired product.  
 
 
Scheme 6:  Synthesis of 1 and 3 substituted hydroxy-acridines.  Reagents 
and conditions:  (a) Cu, CuI, Py, K2CO3, H2O, 110 °C, 4h; (b) POCl3, reflux, 
2h; (c) Phenol, 80 °C, 2h; (d) Amine, Phenol, 100 °C, 1h; (e) BBr3, DCM, rt, 
16h. 
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With two of our desired 9-amino-3-hydroxy acridines in hand, we envisioned a 
simple alkylation with epibromohydrin (shown in Scheme 7) would complete the 
synthesis of our desired analogs 14 and 15.   
 
What we envisioned as a simple, straightforward reaction turned out to be a very 
complex issue that was difficult to decipher.  When using the same methodology 
our lab used to make the acridone analogs,149,150 reaction in a DMF/acetone 
mixture using cesium carbonate as a base yielded a range of results from 
inseparable messes to what appeared to be clean compound by mass 
spectrometry but was a mixture of compounds when the NMR was taken.   
Our first thought was that while cesium carbonate in DMF/acetone worked well 
for acridones and xanthones, that it was not the appropriate base for the acridine 
system.  We proceeded to screen a small number of bases in the alkylation 
reaction of the various 9-amino-3-hydroxy acridine compounds.  Shown in Table 
5 is the result of the base screen.  In the small sampling of bases we used, every 
case in which a non-carbonate base was used, there was no reaction leading to 
a desired product.  When using a carbonate base, switching the solvent to 
methanol gave no reaction.  The only system in which a reaction occurred was 
the combination of a carbonate base in DMF alone or a DMF/acetone mixture.  
 
Scheme 7:  Synthesis of 3-epoxy acridine analogs.  Reagents and conditions:  
(a) Epibromohydrin, Cs2CO3, DMF/Acetone, 70 °C, 16h 
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Having ruled out our choice of base as the most probable reason why the 
reaction was not proceeding as expected, an observation was made about the 
starting 3-hydroxy acridine compounds that led us to the answer as to why these 
reactions were not working as we had hoped. 
 
We noticed that depending on how the 3-hydroxy acridine derivatives were 
handled after purification and what solvent they were dissolved in, they yielded 
different colored solids or solutions.  Sometimes after the 3-hydroxy acridines 
were purified and precipitated, the precipitate was a yellowish solid and other 
times it was an orange-red solid.  In solution, the colors ranged from a yellowish 
solution, which showed no ultraviolet hue when held up to natural light to a 
reddish solution that exhibited a distinct ultraviolet hue similar to that of an 
acridone in natural light.  A closer literature search revealed a reference that had 
been missed that describes the solid and solution phase tautomerisim of 3-
hydroxyacridines151.  Shown in Figure 17 are the two forms of the 3-hydroxy 
acridine; the desired hydroxy form 16 and the keto form 17.  This meant that 
every time we attempted the alkylation reaction, the 3-hydroxy acridine in the 
Base Solvent Temperature Time Result 
Cs2CO3 DMF 70 °C 16h Mixture 
Cs2CO3 DMF/Acetone 50 °C 16h Mixture 
Cs2CO3 MeOH 25 °C 6h No Reaction 
K2CO3 DMF 70 °C 16h Mixture 
t-BuOK DMF 50 °C 6h No Reaction 
NaH DMF 25 °C 6h No Reaction 
Proton Sponge MeCN 25 °C 6h No Reaction 
 
Table 5:  Base screen results (all reactions were conducted in DMF at 70 °C) 
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flask was in a tautomeric equilibrium between the hydroxy and keto form, which 
led to the complex mixtures of products we were seeing.  This is because 
alkylation was likely occurring on the oxygen in the hydroxy form leading to the 
desired product and on the nitrogen in the keto form leading to an undesired 
product.  The two products formed were not separable in our hands using either 
silica gel or alumina flash chromatography.  After deciding there was no good 
way to control which tautomer would be reacting with the alkylating agent, the 
decision was made to change the substitution to the 2 and 4 hydroxy acridines 
which do not have possible tautomers.98 
 
 
 
 
 
 
 
 
 
Figure 17:  Tautomerisim of 3-hydroxy acridines 
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Experimental 
All compounds were synthesized using previously published routes.103 
9-chloro-1-methoxyacridine (4):  Yield:  8%; 1H NMR (600 MHz, CDCl3) δ 4.05 
(s, 3H), 6.87 (d, J = 7.6 Hz, 1H), 7.58-7.69 (m, 2H), 7.76-7.84 (m, 2H), 8.16 (d, J 
= 8.8 Hz, 1H), 8.59 (m, 1H). 
9-chloro-3-methoxyacridine (5):  Yield:  72%; 1H NMR (600 MHz, CDCl3) δ 
4.01 (s, 3H), 7.30 (dd, J = 9.4, 2.5 Hz, 1H), 7.44 (d, J = 2.3 Hz, 1H), 7.58 (m, 1H), 
7.79 (t, J = 7.6 Hz, 1H), 8.14 (d, J = 8.6 Hz, 1H), 8.31 (d, J = 9.1 Hz, 1H), 8.39 (d, 
J = 9.0 Hz, 1H). 
9-chloro-1,3-dimethoxyacridine (6):  Yield:  76%; 1H NMR (600 MHz, CDCl3) δ 
3.97 (s, 3H), 4.00 (s, 3H), 6.51 (d, J = 2.2 Hz, 1H), 7.05 (d, J = 2.2 Hz, 1H), 7.53 
(m, 1H), 7.75 (m, 1H), 8.05 (d, J = 8.8 Hz, 1H), 8.51 (d, J = 8.8 Hz, 1H). 
3-methoxy-N-decylacridin-9-amine (9): Yield: 83 %; 1H NMR (600 MHz, CDCl3) 
δ 0.88 (t, J = 7.6 Hz, 3H), 1.21-1.38 (m, 12H), 1.39-1.49 (m, 2H), 1.72-1.82 (m, 
2H), 3.78 (t, J = 7.4 Hz, 2H), 3.97, s, 3H), 7.03 (dd, J = 9.5, 2.3 Hz, 1H), 7.30-
7.37 (m, 2H), 7.66 (m, 1H), 7.98-8.05 (m, 3H). 
N-(2-(1H-indol-3-yl)ethyl)-3-methoxyacridin-9-amine (10): Yield:  72%; 1H 
NMR (600 MHz, CDCl3) δ 3.22 (t, J = 6.5 Hz, 2H), 3.94 (s, 3H), 4.17 (t, J = 6.6 
Hz, 2H), 6.93 (dd, J = 9.5, 2.6 Hz, 1H), 7.09 (d, J = 2.2 Hz, 1H), 7.16 (m, 1H), 
7.19-7.27 (m, 2H), 7.32 (d, J = 2.2 Hz, 1H), 7.42 (d, J = 8.8 Hz, 1H), 7.61 (t, J = 
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7.6 Hz, 1H), 7.66 (d, J = 7.8 Hz, 1H), 7.82-7.88 (m 2H), 8.00 (d, J = 8.0 Hz, 1H), 
8.39 (br, s, 1H). 
N-(1-benzylpiperidin-4-yl)-3-methoxyacridin-9-amine (11): Yield:  77%; 1H 
NMR (600 MHz, CDCl3) δ 1.67-1.79 (m, 2H), 2.00-2.15 (m, 4H), 2.84-2.92 (m, 
2H), 3.51 (s, 2H), 3.81 (br, s, 1H), 3.98 (s, 3H), 7.09 (dd, J = 9.6, 2.7 Hz, 1H), 
7.27-7.34 (m, 5H), 7.36-7.41 (m, 2H), 7.68 (t, J = 6.9 Hz, 1H), 7.97 (d, J = 9.6 Hz, 
1H), 8.03 (d, J = 8.8 Hz, 1H), 8.06 (d, J = 8.6 Hz, 1H). 
9-(decylamino)acridin-3-ol (12):  Yield:  44%; 1H NMR (600 MHz, DMSO-d6) δ 
0.83 (t, J = 6.8 Hz, 3H), 1.13-1.39 (m, 14H), 1.71-1.81 (m, 2H), 3.87 (t, J = 7.1 
Hz, 2H), 6.78-6.88 (m, 2H), 7.33 (t, J = 7.4 Hz, 1H), 7.63 (d, J = 8.3 Hz, 1H), 7.72 
(t, J = 7.5 Hz, 1H), 8.20 (d, J = 9.6 Hz, 1H), 8.28 (d, J = 8.8 Hz, 1H). 
9-(2-(1H-indol-3-yl)ethylamino)acridin-3-ol (13): Yield:  35%; 1H NMR (600 
MHz, DMSO-d6) δ 3.13-3.18 (m, 2H), 4.05 (t, J = 7.5 Hz, 2H), 6.66 (br, s, 2H), 
6.96 (m, 1H), 7.05 (m, 1H), 7.12-7.22 (m, 2H), 7.32 (d, J = 8.0 Hz, 1H), 7.50-7.60 
(m, 3H), 8.07 (m, 1H), 8.24 (d J = 8.2 Hz, 1H), 10.83 (s, 1H). 
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